



Efstratios Saliakellis, Marie-Catherine Turcotte,
Christophe Faure, and Nikhil Thapar

Introduction

The term pseudo-obstruction literally denotes obstruction in the absence of true mechanical occlusion. Intestinal pseudo-obstruction can be either acute or chronic in nature depending on the duration of obstructive symptoms (chronicity defined as symptoms' duration longer than 6 months) [1, 2]. Chronic intestinal pseudo-obstruction (CIPO) was first described in 1958 by Dudley and colleagues to report a series of 13 patients with symptoms suggestive of intestinal occlusion. These patients underwent exploratory laparotomies, which failed to identify a mechanical cause [3]. The existence of this pathological entity, in both the adult and pediatric population, was later substantiated by a number of other clinicians [4–7]. Research and clinical experience have shown considerable differences between the adult and pediatric population with intestinal pseudo-obstruction and the term pediatric intestinal pseudo-

obstruction (PIPO) is now proposed to specifically characterize the condition in children.

Abnormal antegrade propulsive activity of the gastrointestinal (GI) tract, resulting from processes affecting its neurons, muscles, or interstitial cells of Cajal (ICC), is the pathophysiologic mechanism of PIPO [8]. This functional disability of the gut is responsible for a number of clinical symptoms such as abdominal distention, with or without abdominal pain, nausea, vomiting, and a reduced ability to tolerate oral and/or enteral nutrition [9]. Such symptomatology is, however, non-specific and the condition can remain undiagnosed for a long period of time during which patients may undergo multiple diagnostic investigations and often repeated surgical explorations in an effort to identify the underlying cause [9].

Although, by definition, the small intestine is always involved, any part of the GI tract can be affected in CIPO [1, 2] (Fig. 25.1). Esophageal involvement may lead to dysphagia due to impaired peristalsis, in some cases similar to that seen in achalasia [10, 11]. Involvement of the stomach results in poor feed tolerance due to gastroparesis suggested by the presence of delayed gastric emptying, while involvement of the large bowel and anorectum manifest with constipation (delayed colonic transit) and defecation disorders (sphincteric dysfunction), respectively [1].

This chapter will focus on various aspects of PIPO and will attempt to address areas of controversy by exploring the most recent advances in the overall approach and management of this clinical entity.

E. Saliakellis
4th Department of Paediatrics, Aristotle University Medical
School, Papageorgiou General Hospital, Thessaloniki, Greece

M.-C. Turcotte
Division of Pediatric Gastroenterology, Hepatology and Nutrition,
CHU Sainte-Justine, Montréal, QC, Canada
e-mail: marie.catherine.turcotte@umontreal.ca

C. Faure
Division of Pediatric Gastroenterology, Hepatology and Nutrition,
CHU Sainte-Justine, Montréal, QC, Canada

Département de Pédiatrie, Université de Montréal,
Montréal, QC, Canada
e-mail: christophe.faure@umontreal.ca

N. Thapar (✉)
Gastroenterology, Hepatology and Liver Transplant, Queensland
Children's Hospital, Brisbane, QLD, Australia

School of Medicine, University of Queensland,
Brisbane, QLD, Australia

Woolworths Centre for Child Nutrition Research, Queensland
University of Technology, Brisbane, QLD, Australia
e-mail: Nikhil.Thapar@health.qld.gov.au




Fig. 25.1 Plain abdominal X-ray in a 7-year-old girl with PIPO. Note the enlarged and hugely dilated small bowel loops

Definition

According to an expert European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)/International expert consensus paper on the disorder [12], CIPO in children has clear distinctions from CIPO in adults with the proposal that it be designated pediatric intestinal pseudo-obstruction (PIPO) rather than CIPO and be defined as follows: “Paediatric intestinal pseudo-obstruction is a disorder characterised by the *chronic inability of the gastrointestinal tract to propel its contents mimicking mechanical obstruction, in the absence of any lesion occluding the gut (*chronic is defined as persistence for 2 months from birth or at least 6 months thereafter).” The working group has suggested that the diagnosis of PIPO requires at least two out of four of the following criteria:

1. Objective measure of small intestinal neuromuscular involvement (abnormal validated transit; manometric and/or histopathology studies).
2. Recurrent and/or persistently dilated loops of small intestine with air–fluid levels.
3. Genetic, metabolic, or other abnormalities definitively associated with intestinal pseudo-obstruction.
4. Inability to maintain adequate nutrition and/or growth on normal oral feeding (therefore needing specialized oral and/or enteral nutrition and/or parenteral nutrition support) [12].

Epidemiology

PIPO is a rare disease; scanty epidemiological data exist regarding its incidence and prevalence in both adult and pediatric populations. A survey-based study estimated that approximately 100 infants are born in the United States every year with PIPO, suggesting an incidence of approximately 1 per 40,000 live births [13, 14]. A more recent nationwide survey for pediatric PIPO performed in Japan revealed that among children younger than 15 years of age, the prevalence of PIPO was 3.7 in one million children, of whom 56.5% developed PIPO in the neonatal period [15]. In another nationwide Japanese survey, 138 cases of PIPO were identified, with an estimated prevalence of 1.0 and 0.8 cases, and incidence of 0.21 and 0.24 cases, per 100,000 males and females, respectively [16]. Although adult studies reveal that the disease is more frequent in females [17–19], a recent epidemiological study in US hospitals focusing on PIPO revealed that the incidence of inpatient admission was 29/100,000 patients, with children of male gender and of Caucasian origin being more likely to be admitted [20]. Without doubt the development of national registries is pivotal in order to precisely define the epidemiological characteristics of this orphan disease.

Classification

The classification of PIPO is still challenging. Conditions resulting in PIPO can be classified by whether they primarily affect intestinal nerves (neuropathy), smooth muscle (myopathy), or interstitial cells of Cajal (ICC) (mesenchymopathy). The above-mentioned conditions can be further subdivided into primary or secondary, congenital or acquired, and diffuse or segmental, depending on the mode of inheritance, presentation, likely etiopathogenesis, or what part of the GI tract is involved. Where classification is not possible, they are defined as idiopathic. In truth, there is a considerable overlap [1, 2].

In primary PIPO the disease is usually localized to gastrointestinal tract, whereas in secondary cases there is a systemic disorder that directly or indirectly affects GI tract motility. Notably, in some cases of primary PIPO extra-gastrointestinal involvement may also be part of the clinical picture; examples include disorders of the urinary tract (e.g., hollow visceral myopathy and megacystis-microcolon-intestinal hypoperistalsis syndrome), the nervous system (e.g., central, peripheral, or autonomic neuropathies), and/or mitochondria (e.g., mitochondrial neurogastrointestinal encephalomyopathy [MNGIE]) [2, 21, 22]. Approximately 50% of PIPO cases qualify as secondary PIPO, as presented in Table 25.1 (this is particularly true for adult CIPO patients, whereas in pediatrics the disease is predominantly idiopathic or due to primary causes) [23]. Based on histological findings, both primary and secondary PIPOs can be

further categorized into neuropathies, myopathies, and mesenchymopathies [24–29]. Although the onset of the disease is used to label whether PIPO is congenital or acquired, in children this area needs further elucidation [2, 8, 30].

Etiology and Pathophysiology

The integrity of gastrointestinal sensorimotor function relies on a precise coordination between the autonomic nervous system, enteric nervous system (ENS), ICC, and smooth muscle cells. Any noxious stimulus, as depicted in Table 25.1, which affects the GI neuromusculature may lead to impaired peristalsis and the stasis of luminal contents [1]. Neurologic and metabolic disorders may affect the extrinsic GI neurons, whereas neurotropic viruses could evoke an inflammatory process insulting both the ENS and extrinsic nerve pathways [23, 98]; furthermore, evidence of enteric angiopathy and neuromuscular hypoxia has been identified in patients with mitochondrial neurogastrointestinal encephalomyopathy [150]. Paraneoplastic syndromes could also target the ENS by initiating an inflammatory process that affects the ganglia of the submucosal and myenteric plexuses, via a cellular infiltrate and production of circulating antineuronal antibodies [23, 151]. Some pathologies (e.g., muscular dystrophy) target the enteric smooth muscle fibers whereas entities such as dermatomyositis, scleroderma, Ehlers–Danlos syndrome, and radiation enteritis lead to a mixed neuromyopathic disorder [14, 152, 153]. Celiac disease, hypothyroidism, hypoparathyroidism, and pheochromocytoma could also lead to PIPO by affecting the GI neuromusculature; however, the exact mechanism is not fully defined.

Table 25.1 Classification of chronic intestinal pseudo-obstruction

Primary
<ul style="list-style-type: none"> • Sporadic or familial forms of hollow visceral myopathy/neuropathy (e.g., megacystis-microcolon-intestinal hypoperistalsis syndrome) [7, 31–47] • Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) [22, 48–50] • Hirschsprung disease [51–53] • Neuropathy associated with multiple endocrine neoplasia type IIB [54–56] • Malrotation or gastroschisis [57–59] • Neuropathy post neonatal necrotizing enterocolitis [60]
Secondary
<ul style="list-style-type: none"> • Conditions affecting GI smooth muscle <ul style="list-style-type: none"> – Rheumatological conditions (dermatomyositis/polymyositis, scleroderma, systematic lupus erythematosus, Ehlers–Danlos syndrome) [61–73] – Other (Duchenne’s muscular dystrophy, myotonic dystrophy, amyloidosis, ceroidosis or alternatively reported as brown bowel syndrome) [74–84] • Pathologies affecting the enteric nervous system (familial dysautonomia, primary dysfunction of the autonomic nervous system, autoimmune GI dysmotility neurofibromatosis, diabetic neuropathy, fetal alcohol syndrome, post-viral related PIPO, e.g., CMV, EBV, Varicella Zoster Virus (VZV), John Cunningham Virus (JC virus), Human Herpes Virus (HHV)-6, COVID-19) [85–104] • Endocrinological disorders (hypothyroidism, diabetes, hypoparathyroidism, pheochromocytoma) [105–109] • Metabolic conditions (uremia, porphyria, electrolyte imbalances, e.g., potassium, magnesium, calcium) [110–115] • Other (celiac disease; eosinophilic gastroenteritis; Crohn’s disease; radiation injury; Chagas disease; Kawasaki disease; angioedema; mitochondrial disorders; drugs, e.g., opiates, anthraquinone laxatives, calcium channel blockers, antidepressants; antineoplastic agents, e.g., vinca alkaloids; paraneoplastic, e.g., neuroblastoma; major trauma/surgery; chromosome abnormalities; Creutzfeldt-Jakob disease; Schaaf-Yang syndrome; Treacher Collins syndrome) [116–149]
Idiopathic

Genetics

Elucidation of the genetic basis of PIPO has been somewhat disappointing but has recently improved because of the availability of genome sequencing.

Familial cases of PIPO have been historically recognized with several patterns of inheritance, reflective of the great heterogeneity of PIPO conditions. Both autosomal dominant and recessive modes of inheritance have been described for neuropathic and myopathic types of PIPO [5, 17, 18, 152, 154]. Mutations in filamin A [155], actin γ -2 [45], thymidine phosphorylase (TYMP) [156], polymerase γ (POLG1) [157], and, finally, RAD21 [158] and SGOL1 genes [159] have also been identified in recessive forms of PIPO with an associated syndromic phenotype. More recently, with the advancement in genetic testing, novel mutations (MYLK, LMOD1,

MYL9, SGOL1, MYH11, PDCL3, and ACTG2 variants) have been identified and subsequently related to the etiopathogenesis of chronic intestinal pseudo-obstruction [160–170]. Of these, the smooth muscle actin γ -2 gene (*ACTG2*) is one of the most commonly implicated genes in Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) and prenatal and neonatal myopathic PIPO.

Three patients with a syndromic phenotype of PIPO combined with Waardenburg–Shah features (pigmentary abnormalities and sensorineural deafness) and an underlying “apparently normal” enteric innervation have been demonstrated to carry de novo heterozygous mutations of *SOX10* [171, 172].

Specific genetic mutations are associated to complications. Medullary thyroid carcinoma associated with *MEN2b* and neuroangliomatosis should be searched for by measuring serum calcitonin levels, and early prophylactic thyroidectomy may be considered [173]. In cases with cardiac involvement (*SGOL1*), a pacemaker is indicated since severe bradycardia may occur [159]. Of note, a recently described cohesinopathy with *SGOL1* mutation in four children represents a late-onset but severe PIPO etiology associated with severe bradycardia for which three of the four patients required a pacemaker because of sinus dysfunction at the time of PIPO diagnosis [174]. Filamin A gene on chromosome X as well as thymidine phosphorylase mutations are both associated to seizures and impaired neurological development [155].

Histopathology (See Chap. 19)

The role of histopathology in the confirmation of PIPO is still controversial. Studies in adults reveal that GI histology can be normal in up to 10% of cases, although in the experience of the authors this figure is likely to be higher in children. Adequate full-thickness bowel biopsy (preferably a circumferential sleeve of at least 1–2 cm) is recommended whenever surgery is being considered [8, 30, 175]. Recent initiatives support a more standardized histological approach for the diagnosis in GI dysmotilities such as PIPO [29, 176, 177].

On the basis of histology, PIPO is classified into neuropathy, myopathy, or mesenchymopathy; mixed forms (e.g., neuromyopathy) are also recognized [29, 178–180].

Neuropathies and myopathies can be further subdivided into inflammatory and degenerative. Inflammatory neuropathies are characterized by an infiltration of T-lymphocytes and plasma cells in the myenteric plexuses (myenteric ganglionitis) and neuronal axons (axonopathy); five or more lymphocytes per ganglion are required for the diagnosis of myenteric ganglionitis [29, 181]. Interestingly, patients with lymphocytic infiltration of the myenteric plexus may also develop increased titers of antinuclear antibodies (ANNA-1/anti-Hu, anti-VGKC); the latter could result in neuronal

degeneration and loss via apoptotic and autophagic mechanisms [182–185]. Infiltration of the myenteric ganglia with other cells such as eosinophils and mast cells has also been identified but their clinicopathological significance is yet to be determined [186–189].

Degenerative neuropathies are defined by a decrease in the number of intramural neurons along with changes in nerve cell bodies and axons [176, 181, 190–192]. It has been postulated that aberrant calcium signaling, mitochondrial disorders, production of free radicals, and abnormalities in the function of glial cells initiate apoptotic mechanisms that are involved in the degenerative process [176, 178, 193, 194].

Myopathies are also categorized as inflammatory and degenerative. Inflammatory myopathy, also termed leiomyositis, is characterized by infiltration of T-lymphocytes into both the circular and longitudinal enteric muscle layers and if not treated appropriately with immunosuppressive agents may lead to a severe clinical picture of PIPO [47, 195]. A distinctive presumably acquired degenerative myopathy of unknown etiology, called African degenerative leiomyopathy (ADL), has been described in African populations in southern Africa [196]. The *Ret* gene implicated in Hirschsprung disease appears to confer susceptibility to ADL although the exact mechanism is not known [197].

Histopathology in degenerative myopathies reveals vacuolization and fibrosis of the smooth muscle fibers [198, 199]. In the cases where the longitudinal muscle is more affected compared to the circular muscle layer, diverticula may be identified [200, 201].

Novel techniques in immunohistochemistry, for example, smooth muscle markers such as smoothelin, smooth muscle myosin heavy chain, and histone deacetylase 8, may reveal subtle histopathologic abnormalities otherwise not detectable with conventional methods [202].

Mesenchymopathies are defined by ICC abnormalities (decreased density of ICC network, intracellular abnormalities) and have been identified in PIPO patients [176, 203]. Despite the fact that adequate data exist regarding the role of ICC in the pathogenesis of diabetic gastroparesis, further research is required to elucidate their involvement in the pathogenesis of other GI dysmotilities [29].

Clinical Picture

Signs and Symptoms

The symptomatology varies according to the age at diagnosis and the part of the GI tract, which is primarily affected. Intestinal malrotation is present in approximately one-third of children with congenital PIPO (myopathic and neuropathic) [26]. Cardinal signs and symptoms of PIPO include those of obstruction namely abdominal distention (88%), vomiting (69%, which can be bilious), and constipation

Table 25.2 Clinical symptoms in children with chronic intestinal pseudo-obstruction

Study	Abdominal distension	Vomiting	Constipation	Failure to thrive	Abdominal pain	Diarrhea	Dysphagia
Faure et al. [204]: <i>n</i> = 105	100	94	70	64	46	29	9
Vargas et al. [13]: <i>n</i> = 87	73	50	51	23	NA	21	2
Granata et al. [205]: <i>n</i> = 59	59	31	27	NA	NA	26	NA
Schuffler et al. [32, 226]: <i>n</i> = 30	23	19	20	15	NA	16	NA
Heneyke et al. [25]: <i>n</i> = 44	31	40	31	NA	NA	NA	NA
Muto et al. [15]: <i>n</i> = 62	55	33	9	NA	3	2	NA
Ko et al. [227]: <i>n</i> = 66	49	29	19	NA	4	4	NA
Diamanti et al. [228]: <i>n</i> = 49	NA	41	16	NA	5	14	NA
Total ^a : <i>n</i> = 502	341	337	243	102	58	112	11

NA not available

^a Calculations do not include total percentages due to missing/not reported data indicated as NA

(54%). Abdominal pain, failure to thrive, and diarrhea may also be part of the clinical picture (Table 25.2) [8, 9, 175].

The diagnosis of PIPO is difficult due to the variable clinical presentation and the lack of a specific diagnostic test. The diagnosis should be suspected in children presenting with signs and symptoms of intestinal obstruction without an occluding lesion. The diagnosis of PIPO should be also considered when there is persistent vomiting after a Ladd's procedure for malrotation [58], when intestinal obstruction is associated with bladder dysmotility, or when, in a full-term neonate, there is persistent or recurrent obstruction after exclusion of Hirschsprung disease and hypothyroidism. The differential diagnosis should be carefully considered because establishing a diagnosis of PIPO may be invasive, and the psychological consequences in children and their families are significant.

Dehydration (which can be severe) and malnutrition are often underdiagnosed especially given that weight can be an unreliable measure due to pooling of significant volumes of fluid (third spacing) within distended gut loops. Delayed transit of gut content can also lead to small bowel bacterial overgrowth, which can further exacerbate symptoms of diarrhea and abdominal distention [175].

Extra-intestinal signs and symptoms may as well be part of the PIPO clinical presentation, for example, recurrent urinary tract infections or neurologic abnormalities [21, 156]. Furthermore, patients may complain of symptoms indicative of an underlying disorder that accounts for secondary PIPO (e.g., proximal muscle weakness in dermatomyositis) [62].

The clinical course of PIPO is characterized by exacerbations and remissions; the former can be precipitated by various factors such as surgery, general anesthesia, infections, and emotional stress [30]. In the most severe cases, the natural course of the disease leads to significant deterioration of the intestinal function and ultimately to intestinal failure [9, 175].

Prenatal Symptoms

Although the majority of PIPO cases present in the neonatal period or early infancy, in a few cases the diagnosis is

supported in utero by ultrasonographic findings of polyhydramnios, abdominal distention, and megacystis [8, 30]. Prenatal signs can be detected in about 20% of cases [25, 204]. Megacystis is the most frequently reported sign, whereas dilated bowel at this age is quite rare. This has been noted in megacystis-microcolon-intestinal hypoperistalsis syndrome in which an antenatally enlarged bladder is seen by ultrasound in 88% of cases, hydronephrosis in 53%, increased volume of amniotic fluid in 34%, and gastric distension in only 10% [205]. Although some reports have described the detection of these signs by ultrasound as early as 16 weeks, more often the abnormalities are noted much later in gestation [206]. Antenatally diagnosed non-obstructive megacystis, with neonatal urological symptoms, may precede GI symptoms of pseudo-obstruction by several months.

Clinical Presentation After Birth

Fifty percent to two-thirds of patients present within the first month of life and 80% by 1 year of age. The remainder are detected sporadically throughout the first two decades of life [13, 24, 25, 204]. The clinical presentation is dependent on the age at onset.

Neonatal-Onset Form

In the neonatal form, PIPO presents as severe abdominal distension with bilious vomiting. Although not a universal finding, the abdominal X-ray may show dilated bowel loops with air–fluid levels suggestive of an organic intestinal obstruction. In megacystis-intestinal-hypoperistalsis syndrome, an obstructed urinary system leading to an abdominal distension may be the presenting feature (Fig. 25.2), with symptoms of intestinal obstruction appearing within days to 12 months later. In order to avoid unnecessary surgery, an exploratory laparotomy should be deferred in a neonate with antenatal diagnosis of megacystis. In these neonatal cases, the air–fluid levels on X-ray may be missing. Some affected




Fig. 25.2 Girl neonate with megacystis-microcolon-hypperistalsis syndrome. Left: Colonic opacification showing small non-functional microcolon. Middle: Cystography demonstrating enlarged bladder with “footprints” of digestive loops. Right: Small bowel follow-through

showing malrotation and non-functional small bowel. In neonates, despite the small bowel involvement precluding any enteral feeding, the small bowel loops may not be enlarged converse to older children in whom dilated small bowel is always present

infants may present with abdominal distension and diarrhea secondary to bacterial overgrowth.

PIPO may be mimicked by immaturity of intestinal motility in preterm infants, and thus this diagnosis should be made with caution in this group as the migrating motor complex does not appear in its mature form until a gestational age of 34–35 weeks [207, 208].

Infantile or Late-Onset Form

Major Forms

The symptoms depend on the regions of the gastrointestinal tract primarily involved. Patients present with subacute and/or recurrent episodes of gastric, intestinal, and/or colonic obstruction, necessitating frequent drainage and fluid replacement. This picture may be acute or insidious and chronic and persistent or more often intermittent. Exacerbations may be precipitated by a variety of causes including intercurrent infections, fever, vaccines, general anesthesia, and emotional stress. Diarrhea due to bacterial overgrowth is frequent and may alternate with constipation or episodes of partial obstruction. Stasis of intestinal contents is common in PIPO, and chronic dilatation leads to decompensation and elongation of the bowel, further impairing motility. When fluid and air accumulate in these decompensated loops, torsion caused by mechanical forces is possible. Dehydration (which can be severe) and malnutrition are often underdiagnosed, especially given that weight can be an unreliable measure due to pooling of significant

volumes of fluid (third spacing) within distended gut loops [147]. Mechanical obstruction is normally absent in PIPO patients, but it can, however, be a complication of PIPO, especially after multiple interventions. Volvulus of the splenic flexure and colonic volvulus have been reported in numerous PIPO cases due to torsion of fluid-filled bowel loops [209–211].

Abdominal pain is often severe enough to lead to feeding difficulties resulting in malnutrition. Although esophageal involvement is frequently detected by manometry, dysphagia is rarely reported [212]. Recurrent episodes of functional partial bowel obstruction may be very difficult to differentiate from true mechanical obstruction in the child who has undergone a prior laparotomy and who may have adhesions. A change in symptoms such as the new occurrence of abdominal pain may suggest the latter.

Urinary tract involvement occurs in 33–92% of cases, independent of the type of PIPO [204, 213–215]. Megacystis with a hypocontractile detrusor, and increased bladder capacity and compliance, is the most frequent pattern of urological abnormality (bladder adynamia). Ureterohydronephrosis is seen in 56–68% of cases but vesico-ureteral reflux occurs in less than 10% [215]. Urinary tract infections are frequent but may be asymptomatic. The renal prognosis is generally good, provided that careful, active evaluation and management of the poorly dynamic bladder are performed, to ensure adequate bladder emptying and to prevent urinary tract infection [215]. Where they are taken bladder biopsies show non-specific fibrotic changes in both neuropathic and myopathic forms of PIPO and are thus not useful for subtype classification.

Comorbidities

Malrotation is frequent, especially in neonates (up to 40% of cases) [24, 25, 204], and has been reported in an X-linked familial syndrome associating PIPO, malrotation, and pyloric non-hypertrophic stenosis (Fig. 25.3) [155, 216–218].

The physical examination should encompass a thorough neuromuscular assessment, including testing for pupillary reactions to light and accommodation and external ocular movements to help identify conditions associated with autonomic neuropathy or mitochondrial diseases. Testing for orthostatic stability should be performed in children, especially where postural dizziness, visual disturbances, and sweating abnormalities may suggest the presence of an underlying autonomic neuropathy [44].

External ophthalmoplegia associated with deafness may suggest a mitochondrial defect namely mitochondrial neurogastrointestinal encephalopathy (MNGIE). The onset of symptoms (gastrointestinal or ocular or both) generally occurs during adolescence, although very early-onset disease has been reported (5 months of age) [219]. Peripheral neuropathy and diffuse muscle weakness are the predominant manifestations, although almost all patients have indices of leukoencephalopathy on magnetic resonance imaging



Fig. 25.3 Small bowel follow-through in a 6-month-old boy with an X-linked filamin-A mutation-related PIPO. Note the malrotation, narrowed pylorus, and enlarged bowel loops

(MRI) of the brain [50]. Thymidine phosphorylase activity and plasma thymidine should be measured when suspecting such a diagnosis [220]. Audiological assessment is important to rule out deafness, seen in patients with a *SOX10* gene mutation [171, 172]. The dermatological examination should note signs of connective tissue disease (i.e., scleroderma, dermatomyositis, lupus), including: Raynaud’s phenomenon, skin eruption, palmar erythema, telangiectasia, nodules, and scleroderma of the hands, feet, face, and forearms. Digestive symptoms may precede the skin involvement in these disorders [221].

Neural crest-derived tumors (neuroblastoma) and pheochromocytoma should be suspected and ruled out in children and infants with Chronic Intestinal Pseudo-obstruction (CIP): appropriate computed tomography (CT) imaging and ultrasound studies should be considered to exclude the presence of thoracic or abdominal tumors [222, 223].

Cardiac rhythm and function must be evaluated by electrocardiography (ECG) and echocardiography, since dysfunction of cardiac sinus node may be associated to PIPO [224] and abnormal cardiac contraction should lead one to suspect muscular diseases such as desmin myopathies [225].

Patients with suspected autoimmune GI dysmotility can present with acute or subacute (<8 weeks) onset of GI symptoms, family history of autoimmune diseases, an infectious episode preceding the onset, and extra-intestinal neurological symptoms like dysautonomia [103, 104].

Diagnosis

Chronic intestinal pseudo-obstruction should be suspected in children with early onset, chronic, recurrent, or continuous signs of intestinal obstruction especially where imaging or indeed surgery fails to reveal a mechanical obstruction of the gut (e.g., repeated “normal” exploratory laparotomies). Since the symptoms of PIPO are not specific, a careful differential diagnosis is of paramount importance.

The diagnosis of PIPO should be guided by a structured algorithm, and the ESPGHAN criteria previously described should be applied [12]. A detailed history combined with a meticulous clinical examination and laboratory tests (e.g., serum electrolytes, thyroid stimulating hormone [TSH], lactic acid, specific autoantibodies) may suggest the presence of PIPO and potentially elucidate its cause; however, the establishment of a definitive diagnosis should rely on the use of targeted investigations to: (1) exclude mechanical occlusion of the gut lumen; (2) confirm GI dysmotility, and (3) rule out treatable causes.

The diagnostic tests, which exclude luminal obstruction and confirm the presence of impaired GI motility in children, thus ruling in the diagnosis of PIPO, are discussed below.

Imaging

Since small bowel is always involved, plain abdominal radiographs demonstrate a dilated GI tract with air–fluid levels while contrast GI series can demonstrate anatomical abnormalities (e.g., malrotation, microcolon) and also exclude the presence of gut occlusive lesions [2, 175, 229]. It needs to be kept in mind that a water-soluble substance should be used instead of barium in order to prevent flocculation and inspissation of the contrast material (Figs. 25.1, 25.2, and 25.3).

Novel imaging modalities such as multidetector row helical CT and cine-MRI have been recently performed with promising results in adult series but there are currently limited data regarding their applicability and usefulness in pediatrics [230–235].

Endoscopy

Endoscopy may identify upper or lower bowel mechanical obstruction previously missed on radiology, and allows for duodenal biopsies to exclude mucosal inflammation [224]. Novel techniques (e.g., natural orifice transluminal endoscopic surgery—NOTES) may revolutionize the role of endoscopy in the diagnosis of gut motility disorders by providing the ability of full-thickness biopsy sampling in a safe and minimally invasive way [236, 237].

Motility Investigations

These studies are performed in order to assess the GI motility and to define the underlying pathophysiologic process; in pediatrics, they form the hallmark of diagnosis. The aforementioned studies include gastrointestinal manometries (esophageal, antroduodenal, colonic, anorectal; see Chaps. 10–13), scintigraphy (e.g., gastric emptying, colonic transit; see Chap. 16), electrogastrography, and radio-opaque marker studies (see Chap. 17). The usefulness of novel technologies, such as SmartPill, remains to be determined [8, 238–240].

Although in children with PIPO the involvement of GI tract may be generalized, the small intestine is always affected; thus antroduodenal manometry remains the most discerning test. It needs to be stressed though, that the optimal placement of the manometric catheter is of pivotal significance for a *lege artis* execution and precise interpretation of the this test [241]. Neuropathic cases manifest with uncoordinated contractions, which are of normal amplitude, whereas in myopathic PIPO motor patterns have normal coordination; however, the amplitude of intestinal contrac-

Table 25.3 Features in antroduodenal manometry associated with PIPO

Interdigestive or fasting period
Absence of phase III
Short intervals between phase III
Abnormal phase III
Stationary
Retrograde
Non-migrating burst of contractions ^a
Sustained simultaneous cluster of contractions ^b
Low-amplitude contractions
Postprandial or fed period
Failure to switch to postprandial period
Postprandial hypomotility
Low frequency of contractions
Low amplitude of contractions
Non-migrating cluster of contractions

^aA burst of contractions is defined as sequences of intense irregular pressure waves not satisfying the definition for phase III of MMC

^bA cluster of contractions is defined as the presence of 3–10 pressure waves of slow frequency showing higher amplitude and duration than isolated individual contractions

tions is low [212, 242, 243]. Of note, a newly proposed enhanced Antroduodenal Manometry (ADM) analysis and associated score Great Ormond Street London Antroduodenal Manometry Scoring System (GLASS score) has proven useful in order to discriminate between PIPO and non-PIPO patients and also between distinct histopathological pathologies [244]. Additionally, manometry may facilitate the dynamic assessment of potential pharmacotherapeutic options and feeding strategies (e.g., feasibility of oral or enteral feeds) as well as indicate disease prognosis [245–247]. Antroduodenal manometry features suggestive of PIPO are depicted in Table 25.3 and also described in Chap. 11.

In the most challenging cases, exploratory surgery (laparotomy or laparoscopic-assisted procedures) may be required to definitively exclude mechanical obstruction; however, it should be borne in mind that surgery may precipitate a pseudo-obstructive episode and may also lead to intra-abdominal adhesion formation, which in turn can further complicate future diagnostic or therapeutic procedures as well as lead to secondary mechanical obstruction. Where possible, investigations and then diagnostic/therapeutic surgery should be performed in timeline sequence and in referral centers with relevant expertise in the management of PIPO patients.

Histopathology along with both genetics and antroduodenal manometry can also be very useful in establishing or confirming the diagnosis of PIPO, highlighting the underlying pathophysiologic process and thus aiding the overall management.

Figure 25.4 summarizes the basic steps in the diagnostic evaluation of pediatric patients with suspected PIPO.




Fig. 25.4 Suggested diagnostic algorithm for pediatric intestinal pseudo-obstruction. (Modified from Rudolph CD, Hyman PE, Altschuler SM, Christensen J, Colletti RB, Cucchiara S, et al. Diagnosis and treatment of chronic intestinal pseudo-obstruction in children: report of consensus workshop. *J Pediatr Gastroenterol Nutr.* 1997;24(1):102–12; Thapar N, Saliakellis E, Benninga MA, Borrelli O, Curry J, Faure C, et al. Paediatric Intestinal Pseudo-obstruction: Evidence and Consensus-based Recommendations From an ESPGHAN-Led Expert Group. *J Pediatr Gastroenterol Nutr.* 2018 Jun;66(6):991–1019, with permission [2, 12])

1997;24(1):102–12; Thapar N, Saliakellis E, Benninga MA, Borrelli O, Curry J, Faure C, et al. Paediatric Intestinal Pseudo-obstruction: Evidence and Consensus-based Recommendations From an ESPGHAN-Led Expert Group. *J Pediatr Gastroenterol Nutr.* 2018 Jun;66(6):991–1019, with permission [2, 12])

Differential Diagnosis

PIPO has to be differentiated from mechanical obstruction of the GI tract; the latter is usually characterized by marked abdominal pain (in keeping with the abdominal distention), specific radiologic signs, and manometric patterns [248–250]. Acute functional obstruction (e.g., postoperative ileus), functional GI disorders (e.g., rumination syndrome), and pediatric condition falsification should be considered and appropriately investigated and managed [175, 251, 252]. Table 25.4 provides differential diagnoses of PIPO.

Table 25.4 Differential diagnosis of PIPO in children

Aerophagia
Gastroparesis
Constipation
Rumination syndrome
Cyclic vomiting syndrome
Severe irritable bowel syndrome
Hirschsprung disease
Bacterial overgrowth of various origin (lactase deficiency, disaccharidase deficiency, intestinal duplication)
Aerodigestive fistula
Fabricated induced illness (pediatric condition falsification)

Treatment

The therapeutic approach in PIPO is threefold as it aims to: (1) preserve growth and development by maintaining adequate nutritional intake; (2) preserve and even promote GI motility with combined medical and surgical interventions; and (3) treat disease-related complications or underlying pathologies in the cases of secondary PIPO.

In spite of the limited effect of the currently applied therapeutic options, refinements and evolution in nutritional, medical, and surgical strategies have considerably improved the overall PIPO management [153, 253]. Acute episodes of pseudo-obstruction are generally treated conservatively by intravenous fluid administration (patients remain nil by mouth) and decompression of the affected bowel with drainage of luminal contents via Nasogastric (NG) tube or preformed ostomies. Careful attention to fluid and electrolytes' balance is imperative.

Nutrition

The role of nutrition in PIPO is of paramount significance as it is well established that gut motility improves with optimal nutritional support and declines in the face of under- or malnutrition [8]. In the long term, approximately one-third of pediatric PIPO patients require either partial or total parenteral nutrition, another third requires a degree of intragastric or enteral feeding, whereas the remaining children are able to tolerate sufficient oral nutrition [8]. Within all of the above-mentioned groups, patients able to tolerate feeds may require some dietary modification in order to maintain enteral nutrition and avoid bezoar formation (e.g., low-residue feeds, bite and dissolvable food, restriction diets, hydrolyzed formula).

Although parenteral nutrition is life-saving, it is associated with significant risk of complications, such as central line infections and liver disease; thus, maintaining patients on maximally tolerated enteral nutrition is always strongly encouraged [30]. In the more severe PIPO cases, continuous rather than bolus feeds administered via a gastrostomy or jejunostomy may be better tolerated; the latter is particularly true in those children with impaired gastric motor function [254–256].

Medications

Pharmacotherapy in PIPO patients is mainly confined to the control of intestinal inflammation, suppression of bacterial overgrowth, and promotion of GI motility [246, 256]. In cases of suspected autoimmune GI dysmotility or proven inflammatory process confirmed on full-thickness intestinal biopsies, urgent immunosuppressive therapy with high doses of intravenous steroids, intravenous immunoglobulins, or apheresis should be considered, especially if antineuronal antibodies are detected [103, 104].

Prokinetics (e.g., metoclopramide, domperidone, erythromycin, azithromycin, octreotide, neostigmine, pyridostigmine, prucalopride) and antiemetics (e.g., promethazine, ondansetron) have been used to reduce the severity of nausea and vomiting and improve GI motor function along with enteral feed tolerance [257–263]. The use of some of these agents is limited because of their variable efficacy and unacceptable extra-intestinal side-effects (e.g., metoclopramide, neostigmine). The best studied and tested prokinetics, that is, cisapride and tegaserod, have been withdrawn from the market due to safety concerns [264]. Recent data suggest that antibiotics such as co-amoxiclav may have prokinetic effects

and induce an increased number of migrating motor complexes during the fasting phase of antroduodenal manometry. The need for novel prokinetics with increased safety profile and efficacy has resulted in the development of new products (e.g., prucalopride, aprepitant, ghrelin), but there are limited data regarding their use in pediatric PIPO, further impacted on by restricted availability and licensing [265–267]. Undoubtedly, current medical regimens for PIPO are based on limited literature and/or expert opinion (e.g., combined use of octreotide and erythromycin) and are yet to be tested in future in the context of controlled trials [246, 268].

A small pilot study has recently demonstrated the safety of using fecal microbiota transplantation (FMT) in adults with CIPO, with improvement in symptoms, tolerance of oral feeding, and with no severe adverse events [269]. The utility of FMT in PIPO has not been determined.

Surgery

Surgery remains a valuable intervention on patients with PIPO as it has a multidimensional role in both the diagnostic (e.g., full-thickness biopsies) and therapeutic processes (e.g., insertion of feeding tubes, formation of decompressing ostomies such as gastrostomy, ileostomy) [256, 270, 271].

Indeed, adequate bowel decompression (e.g., gastrostomy, gastrojejunostomy, ileostomy) is crucial not only in providing symptomatic relief by reducing the frequency and the severity of pseudo-obstructive episodes but also in limiting further deterioration of the intestinal motor activity secondary to chronic distention, and in enhancing the tolerance of enteral feeding [24, 25, 256, 270, 272–275]. Long decompression enteral tubes and extensive bowel resections are approaches mainly reported in adult CIPO cohorts but remain untested in terms of practicality, efficacy, and safety in pediatrics [276–278]. Moreover, small bowel resections may lead to short gut syndrome and intestinal failure-associated liver disease [270, 279]. One additional concern is that resections of small intestine may decrease the abdominal domain required for the successful outcome of a potentially necessary future intestinal transplantation [270, 279].

Enterostomy-associated complications (e.g., ostomy prolapse) [280, 281], recurrent pancreatitis [282], diversion colitis [283], excessive fluid losses with high ileostomy output [284], and hemodynamic collapse due to cardiac dysfunction and abdominal compartment syndrome [285] have been reported in patients with chronic intestinal pseudo-obstruction. In patients with gastric and upper digestive tract involvement, gastric perforation and gastric bezoars may occur [204].

Closure of the decompressive ileostomy and restoration of the gut continuity may be attempted in carefully selected patients who have demonstrated significant and clear improvement post ileostomy formation, and have managed to wean parenteral nutrition and remain on full enteral and/or oral feeds without experiencing any troublesome symptoms for a period of at least 2 years. In the opinion of the authors, this is most likely to occur in neuropathic cases of PIPO and least in myopathies. In patients who show recovery with an ileostomy in situ, an ileo-rectal Duhamel pull-through has proven to be the most effective approach [25, 204, 278, 286].

Incidences of the enterostomy-associated complications are not insignificant in PIPO patients as these patients do have an increased rate of stomal prolapse along with a high risk of intestinal necrosis [280, 281]. A meticulously constructed ileostomy combined with careful management of the ostomy, reduces the probability of stomal prolapse thus minimizing the risk of additional intestinal resection [25, 280].

Novel surgical methods involve implantation of devices providing electrical pacing of the GI neuromusculature, but data on children are scanty and limited [287]. Significant progress has been made in regenerative medicine (see Chap. 49), especially with neural cell replacement within the bowel [288, 289]. This has not yet reached clinical trials and is hampered by poor disease characterization [290].

Small bowel transplantation still remains today the only definitive cure for PIPO. The outcomes and survival rates in experienced centers have significantly improved (up to 50% survival rate at 3 years) during the last decade owing to advances in both the surgical approach (e.g., multivisceral transplantation) and the immunosuppressive treatment [291–299] (see Chap. 51).

Natural History, Outcome, and Prognosis

Both pediatric and adult PIPO patients have a severe clinical course, characterized by repetitive relapses and remissions. Regrettably, the low index of suspicion among physicians along with the lack of well-defined diagnostic criteria and readily available facilities in performing specialized diagnostic tests (e.g., manometry), often account for repetitive unnecessary investigations and surgery as well as delayed diagnosis and thus initiation of appropriate management.

The majority of the patients complain of symptoms, which progressively worsen and impact upon the tolerance of enteral nutrition consequently increasing reliance on total parenteral nutrition [227, 228]. The latter in conjunction with disease-related adverse events (e.g., central line infections, impairment of the liver function, immunosuppression after small bowel transplantation, surgical procedures) account

for high morbidity, poor quality of life, and mortality rates up to 30% [13, 25, 32, 204, 205, 226, 300–302].

Despite recent diagnostic and therapeutic advances PIPO in children remains a serious, life-threatening disease with significant impact on the well-being not only of patients themselves but also of their families [301].

Outcomes

In secondary and acquired forms of PIPO, outcome is dependent on the underlying disease responsible for the dysmotility. In cases of destruction of enteric innervation or musculature (autoimmune GI dysmotility), deterioration may occur rapidly without specific treatment [103, 104, 303].

Most often viral infection resolve spontaneously [304] but some chronic cases have been reported [305, 306].

In primary forms of PIPO, the prognosis is poor. In one series of 105 patients, two-thirds required parenteral nutrition and 41% could not be enterally fed. More than half of the patients were Total Parenteral Nutrition (TPN)-dependent for periods ranging from 2 months up to 16 years. Eleven patients (10%) received TPN for more than 10 years. Twenty-four of the 58 patients who underwent bypass surgery were able to eat normally and 20 of those eventually had their stoma closed [204]. Heneyke and colleagues reported that if TPN is required for more than 6 months, the child will probably be TPN-dependent for at least 4 years [25].

Mortality

Progress in the management of parenteral nutrition and the use of bowel decompression have modified the high mortality rate reported in historical series in neonates, for whom up to 90% of patients died before 1 year of age [59, 205]. In series published more recently, mortality varied from 4.8% (3/62 patients) [15] to 10% (10/105) [204], 25% (22/85) [24], and, in one study, just over 30% (14/44) [25]. Of these, underlying PIPO is rarely the primary cause of death except in cases with MEN2b and medullary carcinoma. In pediatric series reported to date, the high mortality rate is almost always due to iatrogenic complications. Long-term TPN-related complications, including central venous catheter-associated sepsis, liver failure, and thrombo-embolic events, as well as post-transplantation complications are the major contributing factors to mortality and morbidity in PIPO patients [24, 25, 204]. Sudden cardiac arrest has been reported in two patients with chronic intestinal pseudo-obstruction [307].

Prognostic Factors

In the large pediatric series published to date, comparison between patients requiring and those no longer requiring artificial feeding shows significant clinical differences in terms of likelihood of neonatal onset, urinary tract involvement, requirement for surgery during the course of the disease, and myopathic disorders, all features that are more frequent in cases with a poor prognosis [24, 25, 204, 227, 228]. The presence of phase III of the Migrating Motor Complex (MMC) on antroduodenal manometry has been reported by several groups to be a good prognostic indicator for tolerance of enteral feeding [212, 254], response to cisapride [245], and mortality [247]. Malrotation is also a factor associated with worse prognosis [25].

Summary

Pediatric PIPO is an enigmatic disease with poorly defined etiopathogenesis, which is reflected on the limitations encountered in both the diagnostic process and therapeutic management. Clearly, multinational initiatives are required to raise awareness, establish stringent diagnostic criteria, and evolve current therapeutic modalities.

References

- Gabbard SL, Lacy BE. Chronic intestinal pseudo-obstruction. *Nutr Clin Pract*. 2013;28(3):307–16.
- Rudolph CD, Hyman PE, Altschuler SM, Christensen J, Colletti RB, Cucchiara S, et al. Diagnosis and treatment of chronic intestinal pseudo-obstruction in children: report of consensus workshop. *J Pediatr Gastroenterol Nutr*. 1997;24(1):102–12.
- Dudley HA, Sinclair IS, McLaren IF, McNair TJ, Newsam JE. Intestinal pseudo-obstruction. *J R Coll Surg Edinb*. 1958;3(3):206–17.
- Naish JM, Capper WM, Brown NJ. Intestinal pseudo-obstruction with steatorrhea. *Gut*. 1960;1:62–6.
- Stephens FO. Syndrome of intestinal pseudo-obstruction. *Br Med J*. 1962;1(5287):1248–1238.2.
- Byrne WJ, Cipel L, Euler AR, Halpin TC, Ament ME. Chronic idiopathic intestinal pseudo-obstruction syndrome in children—clinical characteristics and prognosis. *J Pediatr*. 1977;90(4):585–9.
- Schuffler MD, Pope CE. Studies of idiopathic intestinal pseudo-obstruction. II. Hereditary hollow visceral myopathy: family studies. *Gastroenterology*. 1977;73(2):339–44.
- Hyman P, Thapar N. Gastrointestinal motility and functional disorders in children. In: Faure C, Di Lorenzo C, Thapar N, editors. *Pediatric neurogastroenterology*. New York: Springer; 2013. p. 257–70.
- Thapar N. Clinical picture of intestinal pseudo-obstruction syndrome. *J Pediatr Gastroenterol Nutr*. 2011;53(Suppl 2):S58–9.
- Amiot A, Joly F, Cazals-Hatem D, Merrouche M, Jouet P, Coffin B, et al. Prognostic yield of esophageal manometry in chronic intestinal pseudo-obstruction: a retrospective cohort of 116 adult patients. *Neurogastroenterol Motil*. 2012;24(11):1008–e542.
- Sato H, Abe H, Nagashima A, Yokoyama J, Terai S. Gastrointestinal: a rare case of concomitant type III achalasia and chronic idiopathic intestinal pseudo-obstruction. *J Gastroenterol Hepatol*. 2018;33(3):559.
- Thapar N, Saliakellis E, Benninga MA, Borrelli O, Curry J, Faure C, et al. Paediatric intestinal pseudo-obstruction: evidence and consensus-based recommendations from an ESPGHAN-Led Expert Group. *J Pediatr Gastroenterol Nutr*. 2018;66(6):991–1019.
- Vargas JH, Sachs P, Ament ME. Chronic intestinal pseudo-obstruction syndrome in pediatrics. results of a national survey by members of the North American Society of Pediatric Gastroenterology and Nutrition. *J Pediatr Gastroenterol Nutr*. 1988;7(3):323–32.
- Di Lorenzo C. Pseudo-obstruction: current approaches. *Gastroenterology*. 1999;116(4):980–7.
- Muto M, Matsufuji H, Tomomasa T, Nakajima A, Kawahara H, Ida S, et al. Pediatric chronic intestinal pseudo-obstruction is a rare, serious, and intractable disease: a report of a nationwide survey in Japan. *J Pediatr Surg Int*. 2014;49:1799–803.
- Iida H, Ohkubo H, Inamori M, Nakajima A, Sato H. Epidemiology and clinical experience of chronic intestinal pseudo-obstruction in Japan: a nationwide epidemiologic survey. *J Epidemiol*. 2013;23(4):288–94.
- Stanghellini V, Cogliandro RF, De Giorgio R, Barbara G, Morselli-Labate AM, Cogliandro L, et al. Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. *Clin Gastroenterol Hepatol*. 2005;3(5):449–58.
- Amiot A, Joly F, Alves A, Panis Y, Bouhnik Y, Messing B. Long-term outcome of chronic intestinal pseudo-obstruction adult patients requiring home parenteral nutrition. *Am J Gastroenterol*. 2009;104(5):1262–70.
- Lindberg G, Iwarzon M, Tornblom H. Clinical features and long-term survival in chronic intestinal pseudo-obstruction and enteric dysmotility. *Scand J Gastroenterol*. 2009;44(6):692–9.
- Batra S, Rahman S, Rana MS, Matta S, Darbari A. Epidemiology and healthcare utilization of inpatient admissions in children with pediatric intestinal pseudo-obstruction. *Neurogastroenterol Motil*. 2020;32(4):e13781.
- McLaughlin D, Puri P. Familial megacystis microcolon intestinal hypoperistalsis syndrome: a systematic review. *Pediatr Surg Int*. 2013;29(9):947–51.
- Blondon H, Polivka M, Joly F, Flourie B, Mikol J, Messing B. Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE). *Gastroenterol Clin Biol*. 2005;29(8–9):773–8.
- De Giorgio R, Cogliandro RF, Barbara G, Corinaldesi R, Stanghellini V. Chronic intestinal pseudo-obstruction: clinical features, diagnosis, and therapy. *Gastroenterol Clin N Am*. 2011;40(4):787–807.
- Mousa H, Hyman PE, Cocjin J, Flores AF, Di Lorenzo C. Long-term outcome of congenital intestinal pseudo-obstruction. *Dig Dis Sci*. 2002;47(10):2298–305.
- Heneyke S, Smith VV, Spitz L, Milla PJ. Chronic intestinal pseudo-obstruction: treatment and long term follow up of 44 patients. *Arch Child*. 1999;81(1):21–7.
- Streutker CJ, Huizinga JD, Campbell F, Ho J, Riddell RH. Loss of CD117 (c-kit)- and CD34-positive ICC and associated CD34-positive fibroblasts defines a subpopulation of chronic intestinal pseudo-obstruction. *Am J Surg Pathol*. 2003;27(2):228–35.
- Jain D, Moussa K, Tandon M, Culpepper-Morgan J, Proctor DD. Role of interstitial cells of Cajal in motility disorders of the bowel. *Am J Gastroenterol*. 2003;98(3):618–24.
- Struijs MC, Diamond IR, Pencharz PB, Chang KT, Viero S, Langer JC, et al. Absence of the interstitial cells of Cajal in a child with chronic pseudo-obstruction. *J Pediatr Surg*. 2008;43(12):e25–9.

29. Knowles CH, De Giorgio R, Kapur RP, Bruder E, Farrugia G, Geboes K, et al. The London Classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group. *Gut*. 2010;59(7):882–7.
30. Hyman P. Chronic intestinal pseudo-obstruction. In: Wyllie R, Hyams J, Kay M, editors. *Pediatric gastrointestinal and liver disease*. 4th ed. Philadelphia: Elsevier; 2011. p. 505–11.
31. Puri P, Shinkai M. Megacystis microcolon intestinal hypoperistalsis syndrome. *Semin Pediatr Surg*. 2005;14(1):58–63.
32. Schuffler MD, Pagon RA, Schwartz R, Bill AH. Visceral myopathy of the gastrointestinal and genitourinary tracts in infants. *Gastroenterology*. 1988;94(4):892–8.
33. Martin JE, Benson M, Swash M, Salih V, Gray A. Myofibroblasts in hollow visceral myopathy: the origin of gastrointestinal fibrosis? *Gut*. 1993;34(7):999–1001.
34. Jayachandar J, Frank JL, Jonas MM. Isolated intestinal myopathy resembling progressive systemic sclerosis in a child. *Gastroenterology*. 1988;95(4):1114–8.
35. Lowsky R, Davidson G, Wolman S, Jeejeebhoy KN, Hegele RA. Familial visceral myopathy associated with a mitochondrial myopathy. *Gut*. 1993;34(2):279–83.
36. Schuffler MD, Lowe MC, Bill AH. Studies of idiopathic intestinal pseudoobstruction. I. Hereditary hollow visceral myopathy: clinical and pathological studies. *Gastroenterology*. 1977;73(2):327–38.
37. Jones SC, Dixon MF, Lintott DJ, Axon AT. Familial visceral myopathy. A family with involvement of four generations. *Dig Dis Sci*. 1992;37(3):464–9.
38. Threlkeld AB, Miller NR, Golnik KC, Griffin JW, Kuncel RW, Johns DR, et al. Ophthalmic involvement in myo-neurogastrointestinal encephalopathy syndrome. *Am J Ophthalmol*. 1992;114(3):322–8.
39. Li V, Hostein J, Romero NB, Marsac C, Mezin P, Bost R, et al. Chronic intestinal pseudoobstruction with myopathy and ophthalmoplegia. A muscular biochemical study of a mitochondrial disorder. *Dig Dis Sci*. 1992;37(3):456–63.
40. Ahlfors F, Linander H, Lindstrom M, Veress B, Abrahamsson H. Familial intestinal degenerative neuropathy associated with chronic intestinal pseudo-obstruction. *Neurogastroenterol Motil*. 2011;23(4):347–55, e159.
41. Roper EC, Gibson A, McAlindon ME, Williams LH, Cook JA, Kandler RH, et al. Familial visceral neuropathy: a defined entity? *Am J Med Genet A*. 2005;137A(3):249–54.
42. Niwamoto H, Okamoto E, Toyosaka A, Matsushima Y, Okasora T. Sporadic visceral neuropathy. *Surg Today*. 1995;25(9):763–70.
43. Low PA. Autonomic neuropathies. *Curr Opin Neurol*. 1994;7(5):402–6.
44. Camilleri M, Balm RK, Low PA. Autonomic dysfunction in patients with chronic intestinal pseudo-obstruction. *Clin Auton Res*. 1993;3(2):95–100.
45. Lehtonen HJ, Sipponen T, Tojkander S, Karikoski R, Jarvinen H, Laing NG, et al. Segregation of a missense variant in enteric smooth muscle actin gamma-2 with autosomal dominant familial visceral myopathy. *Gastroenterology*. 2012;143(6):1482–1491.e3.
46. Cho YH, Park JH, do Park Y, Baek MY, Ryu JH, Son GM, et al. Segmental transposition of ileal muscle layers: a rare cause of myopathic pseudoobstruction in a newborn. *J Pediatr Surg*. 2011;46(2):e1–3.
47. Dewit S, de Hertogh G, Geboes K, Tack J. Chronic intestinal pseudo-obstruction caused by an intestinal inflammatory myopathy: case report and review of the literature. *Neurogastroenterol Motil*. 2008;20(4):343–8.
48. Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. *Brain*. 2011;134(Pt 11):3326–32.
49. Perez-Atayde AR. Diagnosis of mitochondrial neurogastrointestinal encephalopathy disease in gastrointestinal biopsies. *Hum Pathol*. 2013;44(7):1440–6.
50. Nishino I, Spinazzola A, Papadimitriou A, Hammans S, Steiner I, Hahn CD, et al. Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. *Ann Neurol*. 2000;47(6):792–800.
51. Puri P, Gosemann JH. Variants of Hirschsprung disease. *Semin Pediatr Surg*. 2012;21(4):310–8.
52. Wu TT, Tsai TW, Chang H, Su CC, Li SY, Lai HS, et al. Polymorphisms of the RET gene in Hirschsprung disease, anorectal malformation and intestinal pseudo-obstruction in Taiwan. *J Formos Med Assoc*. 2010;109(1):32–8.
53. Qualman SJ, Murray R. Aganglionosis and related disorders. *Hum Pathol*. 1994;25(11):1141–9.
54. Qualia CM, Brown MR, Ryan CK, Rossi TM. Oral mucosal neuroomas leading to the diagnosis of multiple endocrine neoplasia type 2B in a child with intestinal pseudo-obstruction. *Gastroenterol Hepatol (N Y)*. 2007;3(3):208–11.
55. Erdogan MF, Gulec B, Gursoy A, Pekcan M, Azal O, Gunhan O, et al. Multiple endocrine neoplasia 2B presenting with pseudo-Hirschsprung's disease. *J Natl Med Assoc*. 2006;98(5):783–6.
56. Grobmyer SR, Guillem JG, O'Riordain DS, Woodruff JM, Shriver C, Brennan MF. Colonic manifestations of multiple endocrine neoplasia type 2B: report of four cases. *Colon Rectum*. 1999;42(9):1216–9.
57. Singh G, Hershman MJ, Loft DE, Payne-James J, Shorvon PJ, Lovell D, et al. Partial malrotation associated with pseudo-obstruction of the small bowel. *Br J Clin Pract*. 1993;47(5):274–5.
58. Devane SP, Coombes R, Smith VV, Bisset WM, Booth IW, Lake BD, et al. Persistent gastrointestinal symptoms after correction of malrotation. *Arch Child*. 1992;67(2):218–21.
59. Bagwell CE, Filler RM, Cutz E, Stringer D, Ein SH, Shandling B, et al. Neonatal intestinal pseudoobstruction. *J Pediatr Surg*. 1984;19(6):732–9.
60. Vanderwinden JM, Dassonville M, Van der Veken E, Cadranet S, De Laet MH. Post-necrotising enterocolitis pseudo-obstruction treated with Cisapride. *Z Kinderchir*. 1990;45(5):282–5.
61. Ohkubo H, Iida H, Takahashi H, Yamada E, Sakai E, Higurashi T, et al. An epidemiologic survey of chronic intestinal pseudo-obstruction and evaluation of the newly proposed diagnostic criteria. *Digestion*. 2012;86(1):12–9.
62. Kleckner FS. Dermatomyositis and its manifestations in the gastrointestinal tract. *Am J Gastroenterol*. 1970;53(2):141–6.
63. Laskin BL, Choyke P, Keenan GF, Miller FW, Rider LG. Novel gastrointestinal tract manifestations in juvenile dermatomyositis. *J Pediatr*. 1999;135(3):371–4.
64. Sjogren RW. Gastrointestinal features of scleroderma. *Curr Opin Rheumatol*. 1996;8(6):569–75.
65. Perlemuter G, Cacoub P, Wechsler B, Hausfater P, Piette JC, Couturier D, et al. Chronic intestinal pseudo-obstruction secondary to connective tissue diseases. *Gastroenterol Clin Biol*. 2001;25(3):251–8.
66. Adachi Y, Yabana T, Kohri T, Ichiyonagi S, Ishida S, Sakamoto H, et al. A case of chronic idiopathic intestinal pseudo-obstruction with Sjogren's syndrome. *Nihon Shokakibyō Gakkai Zasshi*. 1990;87(5):1223–7.
67. Khairullah S, Jasmin R, Yahya F, Cheah TE, Ng CT, Sockalingam S. Chronic intestinal pseudo-obstruction: a rare first manifestation of systemic lupus erythematosus. *Lupus*. 2013;22(9):957–60.
68. Kansal A, Jain A, Thenozhi S, Agarwal V. Intestinal pseudo-obstruction associated with biliary tract dilatation in a patient with systemic lupus erythematosus. *Lupus*. 2013;22(1):87–91.
69. Zhang J, Fang M, Wang Y, Mao J, Sun X. Intestinal pseudo-obstruction syndrome in systemic lupus erythematosus. *Lupus*. 2011;20(12):1324–8.

70. Yamazaki-Nakashimada MA, Rodriguez-Jurado R, Ortega-Salgado A, Gutierrez-Hernandez A, Garcia-Pavon-Osorio S, Hernandez-Bautista V. Intestinal pseudoobstruction associated with eosinophilic enteritis as the initial presentation of systemic lupus erythematosus in children. *J Pediatr Gastroenterol Nutr.* 2009;48(4):482–6.
71. Pelizzo G, Villanacci V, Salemme M, Nakib G, Calcaterra V, Bassotti G. Intestinal pseudo-obstruction due to small bowel α -actin deficiency in a child with Ehlers-Danlos syndrome. *Tech Coloproctol.* 2013;17(6):673–4.
72. Sato T, Ito H, Miyazaki S, Komine S, Hayashida Y. Megacystis and megacolon in an infant with Ehlers-Danlos syndrome. *Acta Paediatr Jpn.* 1993;35(4):358–60.
73. Trapani S, Rubino C, Simonini G, Indolfi G. Gastrointestinal and hepatic involvement in paediatric systemic lupus erythematosus. *Clin Exp Rheumatol.* 2021;39(4):899–906.
74. Camelo AL, Awad RA, Madrazo A, Aguilar F. Esophageal motility disorders in Mexican patients with Duchenne's muscular dystrophy. *Acta Gastroenterol Latinoam.* 1997;27(3):119–22.
75. Bensen ES, Jaffe KM, Tarr PI. Acute gastric dilatation in Duchenne muscular dystrophy: a case report and review of the literature. *Arch Phys Med Rehabil.* 1996;77(5):512–4.
76. Garcia Aroca J, Sanz N, Alonso JL, de Mingo L, Rollan V. Intestinal pseudo-obstruction secondary to systemic neuropathies and myopathies. *Cir Pediatr.* 1994;7(3):115–20.
77. Leon SH, Schuffler MD, Kettler M, Rohrmann CA. Chronic intestinal pseudoobstruction as a complication of Duchenne's muscular dystrophy. *Gastroenterology.* 1986;90(2):455–9.
78. Kim YJ, Kim HS, Park SY, Park SW, Choi YD, Park CH, et al. Intestinal amyloidosis with intractable diarrhea and intestinal pseudo-obstruction. *Korean J Gastroenterol.* 2012;60(3):172–6.
79. Liapis K, Michelis FV, Delimpasi S, Karmiris T. Intestinal pseudo-obstruction associated with amyloidosis. *Amyloid.* 2011;18(2):76–8.
80. Illescas Megias V, Marquez Moreno AJ. Intestinal pseudo-obstruction in Steinert myotonic dystrophy: a clinical-radiological description of 2 cases. *Radiologia.* 2013;55(1):88–90.
81. Bruinenberg JF, Rieu PN, Gabreels FM, Tolboom J. Intestinal pseudo-obstruction syndrome in a child with myotonic dystrophy. *Acta Paediatr.* 1996;85(1):121–3.
82. Boller M, Fiocchi C, Brown CH. Pseudoobstruction in ceroidosis. *AJR Am J Roentgenol.* 1976;127(2):277–9.
83. Michaely HJ, Daroca PJ, Plavsic BM. Brown bowel syndrome—an unusual etiology of pseudo-obstruction of the small intestine. *Rofo.* 2003;175(8):1143–4.
84. Pelizzo G, Calcaterra V, Villanacci V, Mura GB, Bassotti G. Myotonic dystrophy type 1 and pseudo-obstruction in a child with smooth muscle α -actin deficiency and eosinophilic myenteric plexitis. *Turk J Gastroenterol.* 2018;29(2):226–9.
85. Assor P, Negreanu L, Picon L, de Muret A, Gilbert B, Metman E-H. Slowly regressing acute pandysautonomia associated with esophageal achalasia: a case report. *Gastroenterol Clin Biol.* 2008;32(1 Pt 1):46–50.
86. Palao S, Corral I, Vera R, Alonso de Lecinana M. Progressive dysautonomia as initial manifestation of anti-Hu antibody-related syndrome. *Neurologia.* 2007;22(10):899–902.
87. Besnard M, Faure C, Fromont-Hankard G, Ansart-Pirenne H, Peuchmaur M, Cezard JP, et al. Intestinal pseudo-obstruction and acute pandysautonomia associated with Epstein-Barr virus infection. *Am J Gastroenterol.* 2000;95(1):280–4.
88. Taguchi T, Ikeda K, Shono T, Goto S, Kubota M, Kawana T, et al. Autonomic innervation of the intestine from a baby with megacystis microcolon intestinal hypoperistalsis syndrome: I. Immunohistochemical study. *J Pediatr Surg.* 1989;24(12):1264–6.
89. Yamanaka Y, Sakakibara R, Asahina M, Uchiyama T, Liu Z, Yamamoto T, et al. Chronic intestinal pseudo-obstruction as the initial feature of pure autonomic failure. *J Neurol Neurosurg Psychiatry.* 2006;77(6):800.
90. Sinha SK, Kochhar R, Rana S, Bapuraj R, Singh K. Intestinal pseudo-obstruction due to neurofibromatosis responding to cisapride. *Indian J Gastroenterol.* 2000;19(2):83–4.
91. Hanemann CO, Hayward C, Hilton DA. Neurofibromatosis type 1 with involvement of the enteric nerves. *J Neurol Neurosurg Psychiatry.* 2007;78(10):1163–4.
92. Aoki Y, Hosaka S, Kiyosawa K. Intestinal pseudo-obstruction in a diabetic man: role of the mitochondrial A3243G mutation. *Ann Intern Med.* 2002;137(8):703–4.
93. Reid B, DiLorenzo C, Travis L, Flores AF, Grill BB, Hyman PE. Diabetic gastroparesis due to postprandial antral hypomotility in childhood. *Pediatrics.* 1992;90(1 Pt 1):43–6.
94. Hendriks G, McPartland J, El-Matary W. Gastrointestinal presentation and outcome of perinatal cytomegalovirus infection. *BMJ Case Rep.* 2013;2013:bcr2012007671.
95. Atego S, Turck D, Gottrand F, Bonneville M, Wattré P, Lecomte-Houcke M, et al. Chronic intestinal pseudo-obstruction associated with cytomegalovirus infection in an infant. *J Pediatr Gastroenterol Nutr.* 1996;23(4):457–60.
96. Precupanu CM, Girodet J, Mariani P, Zanni M, Mathiot C, Escande MC, et al. Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation. *Am J Hematol.* 2009;84(2):127–8.
97. Tanida E, Izumi M, Abe T, Tsuchiya I, Okuma K, Uchida E, et al. Disseminated varicella-zoster virus infection complicated with severe abdominal pain and colonic pseudo-obstruction. *Nihon Shokakibyō Gakkai Zasshi.* 2013;110(5):839–45.
98. De Giorgio R, Ricciardiello L, Naponelli V, Selgrad M, Piazzi G, Feliciani C, et al. Chronic intestinal pseudo-obstruction related to viral infections. *Transpl Proc.* 2010;42(1):9–14.
99. Selgrad M, De Giorgio R, Fini L, Cogliandro RF, Williams S, Stanghellini V, et al. JC virus infects the enteric glia of patients with chronic idiopathic intestinal pseudo-obstruction. *Gut.* 2009;58(1):25–32.
100. Uc A, Vasiliauskas E, Piccoli DA, Flores AF, Di Lorenzo C, Hyman PE. Chronic intestinal pseudoobstruction associated with fetal alcohol syndrome. *Dig Dis Sci.* 1997;42(6):1163–7.
101. Saraiva S, Simões C, Verdelho Machado M, Freitas C, Baldaia C, Valente A, et al. Human herpesvirus 6 reactivation associated with intestinal pseudo-obstruction in a renal transplant recipient. *Exp Clin Transplant.* 2022;20(2):209–12.
102. Herdes RE, Cagil Y, Namjoshi S, Hassan M. Initial presentation of a pediatric intestinal pseudo-obstruction episode after SARS-CoV-2 virus (COVID-19) infection. *JPGN Rep.* 2021;2(2):e059.
103. Flanagan EP, Saito YA, Lennon VA, McKeon A, Fealey RD, Szarka LA, et al. Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility. *Neurogastroenterol Motil.* 2014;26(9):1285–97.
104. Blackburn KM, Kubiliun M, Harris S, Vernino S. Neurological autoimmune disorders with prominent gastrointestinal manifestations: a review of presentation, evaluation, and treatment. *Neurogastroenterol Motil.* 2019;31(10):e13611.
105. Abboud B, Sayegh R, Medlej R, Halaby G, Saade C, Farah P. A rare manifestation of hypothyroidism: intestinal obstruction. Report of 2 cases and review of the literature. *J Med Liban.* 1999;47(6):364–6.
106. Bassotti G, Pagliacci MC, Nicoletti I, Pelli MA, Morelli A. Intestinal pseudoobstruction secondary to hypothyroidism. Importance of small bowel manometry. *J Clin Gastroenterol.* 1992;14(1):56–8.
107. Siegrist D, Teuscher AU, Ruchti C. Intestinal paralysis in long-term diabetes mellitus. *Praxis (Bern 1994).* 1998;87(22):769–72.

108. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. *Am J Gastroenterol*. 2013;108(1):18–37. quiz 38
109. Wu HW, Liou WP, Chou CC, Chen YH, Loh CH, Wang HP. Pheochromocytoma presented as intestinal pseudo-obstruction and hyperamylasemia. *Am J Emerg Med*. 2008;26(8):971.e1–4.
110. Geelhoed GW. Colonic pseudo-obstruction in surgical patients. *Am J Surg*. 1985;149(2):258–65.
111. Lutz P, Maring D, Tschampa HJ, Sauerbruch T. A 25-year-old patient with colonic pseudo-obstruction, hyponatremia, hypertension, and diffuse pain. *Med Klin Munich*. 2010;105(4):267–72.
112. Negrini S, Zoppi G, Setti M, Cappellini MD, Indiveri F. Paralytic ileus and liver failure—an unusual presentation of advanced erythropoietic protoporphyria. *Dig Dis Sci*. 2009;54(2):411–5.
113. Koberstein B, Eysselein VE, Balzer K, Muller MK, Eberlein G, Singer MV, et al. Paralytic ileus as an initial manifestation of malignant VIPoma of the pancreas—case report with review of the literature. *Z Gastroenterol*. 1990;28(6):295–301.
114. Sundar U, Lakkas Y, Asole D, Vaidya M. Gitelman’s syndrome presenting as recurrent paralytic ileus due to chronic renal tubular K⁺ wasting. *J Assoc Physicians India*. 2010;58:322–4.
115. Golzarian J, Scott HW Jr, Richards WO. Hypermagnesemia-induced paralytic ileus. *Dig Dis Sci*. 1994;39(5):1138–42.
116. Matta R, Aramouni E, Mouawad P, Diab N. Celiac disease presenting as acute colonic pseudo-obstruction. *J Med Liban*. 2012;60(2):110–2.
117. Cluysenaer OJ, van Tongeren JH. Pseudo-obstruction in coeliac sprue. *Neth J Med*. 1987;31(5–6):300–4.
118. Cluysenaer OJ, van Tongeren JH. Coeliac disease presenting with intestinal pseudo-obstruction. *Gut*. 1985;26(5):538.
119. Ooms AH, Verheij J, Hulst JM, Vlot J, van der Starre C, de Ridder L, et al. Eosinophilic myenteric ganglionitis as a cause of chronic intestinal pseudo-obstruction. *Virchows Arch*. 2012;460(1):123–7.
120. Losanoff JE, Kjossev KT, Katrov ET. Eosinophilic enterocolitis and visceral neuropathy with chronic intestinal pseudo-obstruction. *J Clin Gastroenterol*. 1999;28(4):368–71.
121. Myrhoj T, Ladefoged K, Jarnum S. Chronic intestinal pseudo-obstruction in patients with extensive bowel resection for Crohn’s disease. *Scand J Gastroenterol*. 1988;23(3):380–4.
122. Carethers JM, McDonnell WM, Owyang C, Scheiman JM. Massive secretory diarrhea and pseudo-obstruction as the initial presentation of Crohn’s disease. *J Clin Gastroenterol*. 1996;23(1):55–9.
123. Rolachon A, Bost R, Bichard P, Zarski JP, Hostein J. Radiotherapy: a rare etiology of chronic intestinal pseudo-obstruction. *Gastroenterol Clin Biol*. 1993;17(3):229–30.
124. Husebye E, Hauer-Jensen M, Kjørstad K, Skar V. Severe late radiation enteropathy is characterized by impaired motility of proximal small intestine. *Dig Dis Sci*. 1994;39(11):2341–9.
125. Meneghelli UG. Chagasic enteropathy. *Rev Soc Bras Med Trop*. 2004;37(3):252–60.
126. Tiao MM, Huang LT, Liang CD, Ko SF. Atypical Kawasaki disease presenting as intestinal pseudo-obstruction. *J Formos Med Assoc*. 2006;105(3):252–5.
127. Eck SL, Morse JH, Janssen DA, Emerson SG, Markovitz DM. Angioedema presenting as chronic gastrointestinal symptoms. *Am J Gastroenterol*. 1993;88(3):436–9.
128. Shemer SA, Marley L, Miller F. Intestinal pseudo-obstruction due to mitochondrial cytopathy. *ANZ J Surg*. 2010;80(7–8):571.
129. Bianchi A, Ubach M. Acute colonic pseudo-obstruction caused by opiates treated with naloxone. *Med Clin (Barc)*. 1994;103(2):78.
130. Kapur RP. Neuropathology of paediatric chronic intestinal pseudo-obstruction and related animal models. *J Pathol*. 2001;194(3):277–88.
131. Muller-Lissner SA. Adverse effects of laxatives: fact and fiction. *Pharmacology*. 1993;47(Suppl 1):138–45.
132. Schultz HS, Vernon B. Intestinal pseudo-obstruction related to using verapamil. *West J Med*. 1989;151(5):556–8.
133. Lemye M, Chaaban R, Collet F. Psychotic woman with painful abdominal distension. Life-threatening psychotropic drug-induced gastrointestinal hypomotility. *Ann Emerg Med*. 2009;54(5):756–9.
134. McMahon AJ. Amitriptyline overdose complicated by intestinal pseudo-obstruction and caecal perforation. *Postgrad Med J*. 1989;65(770):948–9.
135. Esquerdo Galiana G, Briceno Garcia H, Llorca Ferrandiz C, Cervera Grau JM. Paralytic ileus due to vinorelbine. *Clin Transl Oncol*. 2005;7(4):169–70.
136. Saito H, Yamamoto T, Kimura M, Shimokata K. Prostaglandin F₂ alpha in the treatment of vinca alkaloid-induced ileus. *Am J Med*. 1993;95(5):549–51.
137. Mifune D, Tsukada H, Hosoi M, Okajima M, Yokoyama A. Chronic intestinal pseudo-obstruction as a paraneoplastic presentation of limited-stage small cell lung cancer. *Nihon Kokyuki Gakkai Zasshi*. 2010;48(6):439–43.
138. Wildhaber B, Niggli F, Stallmach T, Willi U, Stauffer UG, Sacher P. Intestinal pseudoobstruction as a paraneoplastic syndrome in ganglioneuroblastoma. *Eur J Pediatr Surg*. 2002;12(6):429–31.
139. Simonelli M, Banna GL, Santoro A. Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy. *Tumori*. 2009;95(2):243–7.
140. Rex DK. Acute colonic pseudo-obstruction (Ogilvie’s syndrome). *Gastroenterologist*. 1994;2(3):233–8.
141. Yilmazlar A, Iscimen R, Bilgen OF, Ozguc H. Ogilvie’s syndrome following bilateral knee arthroplasty: a case report. *Acta Orthop Traumatol Turc*. 2012;46(3):220–2.
142. Hou JW, Wang TR. Amelia, dextrocardia, asplenia, and congenital short bowel in deleted ring chromosome 4. *J Med Genet*. 1996;33(10):879–81.
143. Gutiérrez Pérez C, Lastra Aras E, Gómez Bravo R, Chivato Martín-Falquina I, Cuenca Zarzuela A, Rodríguez Ledesma I, et al. Chronic intestinal pseudo-obstruction: diagnostic and prognostic utility of ANNA-1/Anti-Hu onconeural antibodies. *Rev Espanola Enfermedades Dig*. 2022;114(3):175–6.
144. Donate Ortega J, Sánchez Aldehuelo R, Teruel Sánchez-Vegazo C, González Martín JA, de la Serna Gamboa Á, López Jerez A, et al. Anti-Hu-mediated paraneoplastic chronic intestinal pseudo-obstruction associated with extraskeletal myxoid chondrosarcoma. *Rev Espanola Enfermedades Dig*. 2021;113(12):849.
145. Videira G, Ferro D, Guimarães S, Pinto M, Santos E. Intestinal pseudo-obstruction in Creutzfeldt-Jakob disease. *Clin Auton Res*. 2021;31(6):795–7.
146. Castaneda D, Miret R, Rajagopalan R, Castillo M, Gonzalez A, Castro F. Chronic intestinal pseudo-obstruction due to incidentally found thymoma. *ACG Case Rep J*. 2021;8(5):e00608.
147. Karunakar P, Gunasekaran D, Ramamoorthy JG, Krishnamurthy S, Anantharaj A, Sasidharan A, et al. Kawasaki disease presenting with intestinal pseudo-obstruction. *Indian J Pediatr*. 2020;87(7):569–70.
148. Bayat A, Bayat M, Lozoya R, Schaaf CP. Chronic intestinal pseudo-obstruction syndrome and gastrointestinal malrotation in an infant with schAAF-yang syndrome - expanding the phenotypic spectrum. *Eur J Med Genet*. 2018;61(10):627–30.
149. Giabicani E, Lemale J, Dainese L, Boudjemaa S, Coulomb A, Tounian P, et al. Chronic intestinal pseudo-obstruction in a child with Treacher Collins syndrome. *Arch Pediatr*. 2017;24(10):1000–4.
150. Boschetti E, D’Angelo R, Tardio ML, Costa R, Giordano C, Accarino A, et al. Evidence of enteric angiopathy and neuromuscular hypoxia in patients with mitochondrial neurogastrointestinal encephalomyopathy. *Am J Physiol Gastrointest Liver Physiol*. 2021;320(5):G768–79.

151. Koike H, Sobue G. Paraneoplastic neuropathy. *Handb Clin Neurol*. 2013;115:713–26.
152. Stanghellini V, Corinaldesi R, Barbara L. Pseudo-obstruction syndromes. *Baillieres Clin Gastroenterol*. 1988;2(1):225–54.
153. Stanghellini V, Cogliandro RF, de Giorgio R, Barbara G, Salvioli B, Corinaldesi R. Chronic intestinal pseudo-obstruction: manifestations, natural history and management. *Neurogastroenterol Motil*. 2007;19(6):440–52.
154. Stanghellini V, Camilleri M, Malagelada JR. Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. *Gut*. 1987;28(1):5–12.
155. Gargiulo A, Auricchio R, Barone MV, Cotugno G, Reardon W, Milla PJ, et al. Filamin A is mutated in X-linked chronic idiopathic intestinal pseudo-obstruction with central nervous system involvement. *Am J Hum Genet*. 2007;80(4):751–8.
156. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. *Science*. 1999;283(5402):689–92.
157. Giordano C, Powell H, Leopizzi M, De Curtis M, Travaglini C, Sebastiani M, et al. Fatal congenital myopathy and gastrointestinal pseudo-obstruction due to POLG1 mutations. *Neurology*. 2009;72(12):1103–5.
158. Bonora E, Bianco F, Cordeddu L, Bamshad M, Francescatto L, Dowless D, et al. Mutations in RAD21 disrupt regulation of APOB in patients with chronic intestinal pseudo-obstruction. *Gastroenterology*. 2015;148(4):771–782.e11.
159. Chetaille P, Preuss C, Burkhard S, Côté J-M, Houde C, Castilloux J, et al. Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm. *Nat Genet*. 2014;46(11):1245–9.
160. Wang Q, Zhang J, Wang H, Feng Q, Luo F, Xie J. Compound heterozygous variants in MYH11 underlie autosomal recessive megacystis-microcolon-intestinal hypoperistalsis syndrome in a Chinese family. *J Hum Genet*. 2019;64(11):1067–73.
161. Kloth K, Renner S, Burmester G, Steinemann D, Pabst B, Lorenz B, et al. 16p13.11 microdeletion uncovers loss-of-function of a MYH11 missense variant in a patient with megacystis-microcolon-intestinal-hypoperistalsis syndrome. *Clin Genet*. 2019;96(1):85–90.
162. Ravenscroft G, Pannell S, O’Grady G, Ong R, Ee HC, Faiz F, et al. Variants in *ACTG2* underlie a substantial number of Australasian patients with primary chronic intestinal pseudo-obstruction. *Neurogastroenterol Motil*. 2018;30(9):e13371.
163. Billon C, Molin A, Poirsier C, Clemenson A, Dauge C, Grelet M, et al. Fetal megacystis-microcolon: genetic mutational spectrum and identification of PDCL3 as a novel candidate gene. *Clin Genet*. 2020;98(3):261–73.
164. Moreno CA, Sobreira N, Pugh E, Zhang P, Steel G, Torres FR, et al. Homozygous deletion in MYL9 expands the molecular basis of megacystis-microcolon-intestinal hypoperistalsis syndrome. *Eur J Hum Genet*. 2018;26(5):669–75.
165. Halim D, Brosens E, Muller F, Wangler MF, Beaudet AL, Lupski JR, et al. Loss-of-function variants in MYLK cause recessive megacystis microcolon intestinal hypoperistalsis syndrome. *Am J Hum Genet*. 2017;101(1):123–9.
166. Halim D, Wilson MP, Oliver D, Brosens E, Verheij JBG, Han Y, et al. Loss of LMOD1 impairs smooth muscle cytocontractility and causes megacystis microcolon intestinal hypoperistalsis syndrome in humans and mice. *Proc Natl Acad Sci*. 2017;114(13):E2739–47.
167. Gamboa HE, Sood M. Pediatric intestinal pseudo-obstruction in the era of genetic sequencing. *Curr Gastroenterol Rep*. 2019;21(12):70.
168. Venkatesh V, Aneja A, Seetharaman K, Anushree N, Rana SS, Lal SB. A novel cohesinopathy causing chronic intestinal pseudo obstruction in 2 siblings and literature review. *J Neurogastroenterol Motil*. 2021;27(3):436–7.
169. Matera I, Bordo D, Di Duca M, Lerone M, Santamaria G, Pongiglione M, et al. Novel *ACTG2* variants disclose allelic heterogeneity and bi-allelic inheritance in pediatric chronic intestinal pseudo-obstruction. *Clin Genet*. 2021;99(3):430–6.
170. Hahn JW, Moon SY, Kim MS, Woo MH, Sohn MJ, Kim H-Y, et al. *ACTG2* variants in pediatric chronic intestinal pseudo-obstruction with megacystis. *J Neurogastroenterol Motil*. 2022;28(1):104–10.
171. Pingault V, Guiochon-Mantel A, Bondurand N, Faure C, Lacroix C, Lyonnet S, et al. Peripheral neuropathy with hypomyelination, chronic intestinal pseudo-obstruction and deafness: a developmental ‘neural crest syndrome’ related to a *SOX10* mutation. *Ann Neurol*. 2000;48(4):671–6.
172. Pingault V, Girard M, Bondurand N, Dorkins H, Van Maldergem L, Mowat D, et al. *SOX10* mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism. *Hum Genet*. 2002;111(2):198–206.
173. Navarro J, Sonsino E, Boige N, Nabarra B, Ferkadji L, Mashako LM, et al. Visceral neuropathies responsible for chronic intestinal pseudo-obstruction syndrome in pediatric practice: analysis of 26 cases. *J Pediatr Gastroenterol Nutr*. 1990;11(2):179–95.
174. Poinot P, Castilloux J, Andelfinger G, Faure C. A170 A new pediatric intestinal pseudo-obstruction syndrome by *SGOL1* mutation: a late-onset but severe digestive phenotype. *J Can Assoc Gastroenterol*. 2019;2(Suppl_2):336.
175. Faure C. Chronic intestinal pseudo-obstruction syndrome. In: Walker WA, Goulet O, Kleinman RE, Sherman PM, Shneider BL, Sanderson IR, editors. *Pediatric gastrointestinal disease*. 4th ed. Ontario: BC Decker; 2004. p. 1044–54.
176. Knowles CH, De Giorgio R, Kapur RP, Bruder E, Farrugia G, Geboes K, et al. Gastrointestinal neuromuscular pathology: guidelines for histological techniques and reporting on behalf of the Gastro 2009 International Working Group. *Acta Neuropathol*. 2009;118(2):271–301.
177. Knowles CH, Lindberg G, Panza E, De Giorgio R. New perspectives in the diagnosis and management of enteric neuropathies. *Nat Rev Gastroenterol Hepatol*. 2013;10(4):206–18.
178. De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology. *Neurogastroenterol Motil*. 2004;16(5):515–31.
179. De Giorgio R, Sarnelli G, Corinaldesi R, Stanghellini V. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. *Gut*. 2004;53(11):1549–52.
180. Di Nardo G, Blandizzi C, Volta U, Colucci R, Stanghellini V, Barbara G, et al. Review article: Molecular, pathological and therapeutic features of human enteric neuropathies. *Aliment Pharmacol Ther*. 2008;28(1):25–42.
181. De Giorgio R, Guerrini S, Barbara G, Stanghellini V, De Ponti F, Corinaldesi R, et al. Inflammatory neuropathies of the enteric nervous system. *Gastroenterology*. 2004;126(7):1872–83.
182. De Giorgio R, Bovara M, Barbara G, Canossa M, Sarnelli G, De Ponti F, et al. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. *Gastroenterology*. 2003;125(1):70–9.
183. Hubball A, Martin JE, Lang B, De Giorgio R, Knowles CH. The role of humoral autoimmunity in gastrointestinal neuromuscular diseases. *Prog Neurobiol*. 2009;87(1):10–20.
184. Hubball AW, Lang B, Souza MAN, Curran OD, Martin JE, Knowles CH. Voltage-gated potassium channel (K(v) 1) autoantibodies in patients with chagasic gut dysmotility and distribution of K(v) 1 channels in human enteric neuromusculature (autoantibodies in GI dysmotility). *Neurogastroenterol Motil*. 2012;24(8):719–28, e344.
185. De Giorgio R, Barbara G, Stanghellini V, De Ponti F, Salvioli B, Tonini M, et al. Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal

- motor dysfunction: a study of three cases. *Am J Gastroenterol*. 2002;97(9):2454–9.
186. Schappi MG, Smith VV, Milla PJ, Lindley KJ. Eosinophilic myenteric ganglionitis is associated with functional intestinal obstruction. *Gut*. 2003;52(5):752–5.
 187. Murch S. Allergy and intestinal dysmotility—evidence of genuine causal linkage? *Curr Opin Gastroenterol*. 2006;22(6):664–8.
 188. Bassotti G, Villanacci V. Mast cells in intestinal motility disorders: please also look beyond IBS. *Dig Dis Sci*. 2012;57(9):2475–6. author reply 2476
 189. Bassotti G, Villanacci V, Nascimbeni R, Cadei M, Manenti S, Antonelli E, et al. Increase of colonic mast cells in obstructed defecation and their relationship with enteric glia. *Dig Dis Sci*. 2012;57(1):65–71.
 190. Mann SD, Debinski HS, Kamm MA. Clinical characteristics of chronic idiopathic intestinal pseudo-obstruction in adults. *Gut*. 1997;41(5):675–81.
 191. Lindberg G, Tornblom H, Iwarzon M, Nyberg B, Martin JE, Veress B. Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility. *Gut*. 2009;58(8):1084–90.
 192. Knowles CH, Silk DB, Darzi A, Veress B, Feakins R, Raimundo AH, et al. Deranged smooth muscle alpha-actin as a biomarker of intestinal pseudo-obstruction: a controlled multinational case series. *Gut*. 2004;53(11):1583–9.
 193. Bassotti G, Villanacci V, Antonelli E, Morelli A, Salerno B. Enteric glial cells: new players in gastrointestinal motility? *Lab Investig*. 2007;87(7):628–32.
 194. Bassotti G, Villanacci V. Can ‘functional’ constipation be considered as a form of enteric neuro-gliopathy? *Glia*. 2011;59(3):345–50.
 195. Oton E, Moreira V, Redondo C, Lopez-San-Roman A, Foruny JR, Plaza G, et al. Chronic intestinal pseudo-obstruction due to lymphocytic leiomyositis: is there a place for immunomodulatory therapy? *Gut*. 2005;54(9):1343–4.
 196. Kaschula RO, Cywes S, Katz A, Louw JH. Degenerative leiomyopathy with massive megacolon. Myopathic form of chronic idiopathic intestinal pseudo-obstruction occurring in indigenous Africans. *Perspect Pediatr Pathol*. 1987;11:193–213.
 197. Van Rensburg C, Moore SW, Zaahl M. RET promoter variations in familial African degenerative leiomyopathy (ADL): first report of a possible genetic-environmental interaction. *Pediatr Surg Int*. 2012;28(12):1235–8.
 198. Smith JA, Hauser SC, Madara JL. Hollow visceral myopathy: a light- and electron-microscopic study. *Am J Surg Pathol*. 1982;6(3):269–75.
 199. Schuffler MD. Chronic intestinal pseudo-obstruction syndromes. *Med Clin North Am*. 1981;65(6):1331–58.
 200. Bardosi A, Creutzfeldt W, DiMauro S, Felgenhauer K, Friede RL, Goebel HH, et al. Myo-, neuro-, gastrointestinal encephalopathy (MNGIE syndrome) due to partial deficiency of cytochrome-c-oxidase. A new mitochondrial multisystem disorder. *Acta Neuropathol*. 1987;74(3):248–58.
 201. Giordano C, Sebastiani M, De Giorgio R, Travaglini C, Tancredi A, Valentino ML, et al. Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion. *Am J Pathol*. 2008;173(4):1120–8.
 202. Wedel T, Van Eys GJ, Waltregny D, Glenisson W, Castronovo V, Vanderwinden JM. Novel smooth muscle markers reveal abnormalities of the intestinal musculature in severe colorectal motility disorders. *Neurogastroenterol Motil*. 2006;18(7):526–38.
 203. Farrugia G. Interstitial cells of Cajal in health and disease. *Neurogastroenterol Motil*. 2008;20(Suppl 1):54–63.
 204. Faure C, Goulet O, Atego S, Breton A, Tounian P, Ginies JL, et al. Chronic intestinal pseudoobstruction syndrome: clinical analysis, outcome, and prognosis in 105 children. French-Speaking Group of Pediatric Gastroenterology. *Dig Dis Sci*. 1999;44(5):953–9.
 205. Granata C, Puri P. Megacystis-microcolon-intestinal hypoperistalsis syndrome. *J Pediatr Gastroenterol Nutr*. 1997;25(1):12–9.
 206. Chapman AH, McNamara M, Porter G. The acute contrast enema in suspected large bowel obstruction: value and technique. *Clin Radiol*. 1992;46(4):273–8.
 207. Di Lorenzo C. Surgery in intestinal pseudo-obstruction: pro. *J Pediatr Gastroenterol Nutr*. 2005;41(Suppl 1):S64–5.
 208. Zakharov NL, Bairov GA. The treatment of newborns with gastroschisis. *Vestn Khir Im Grek*. 1992;149(11–12):346–50.
 209. de Betue CT, Boersma D, Oomen MW, Benninga MA, de Jong JR. Volvulus as a complication of chronic intestinal pseudo-obstruction syndrome. *Eur J Pediatr*. 2011;170(12):1591–5.
 210. Osuka A, Ikegami R, Watanabe Y. Splenic flexure volvulus in a child with chronic idiopathic intestinal pseudo-obstruction syndrome. *Pediatr Surg Int*. 2006;22(10):833–5.
 211. Zubarovskii IN, Plutakhin KA. The Ogilvie syndrome after restorative surgery on the large intestine. *Vestn Khir Im Grek*. 2009;168(5):71–2.
 212. Boige N, Faure C, Cargill G, Mashako LM, Cordeiro-Ferreira G, Viarme F, et al. Manometrical evaluation in visceral neuropathies in children. *J Pediatr Gastroenterol Nutr*. 1994;19(1):71–7.
 213. Higman D, Peters P, Stewart M. Familial hollow visceral myopathy with varying urological manifestations. *Br J Urol*. 1992;70(4):435–8.
 214. Ghavamian R, Wilcox DT, Duffy PG, Milla PJ. The urological manifestations of hollow visceral myopathy in children. *J Urol*. 1997;158(3 Pt 2):1286–90.
 215. Lapointe SP, Rivet C, Goulet O, Fekete CN, Lortat-Jacob S. Urological manifestations associated with chronic intestinal pseudo-obstructions in children. *J Urol*. 2002;168(4 Pt 2):1768–70.
 216. Auricchio A, Brancolini V, Casari G, Milla PJ, Smith VV, Devoto M, et al. The locus for a novel syndromic form of neuronal intestinal pseudoobstruction maps to Xq28. *Am J Hum Genet*. 1996;58(4):743–8.
 217. Vignon H. Disorders of transit in acute pancreatitis and peritonitis. *Ann Anesthesiol Fr*. 1974;15 SPEC NO 1:85–7.
 218. Wimmer RD, Skibba RM. Pseudo-obstruction of colon: resolution following paracentesis. *J Kans Med Soc*. 1976;77(9):387–8.
 219. Sule AZ, Uba AF, Kidmas AT. Acute colonic pseudo-obstruction (Ogilvie’s syndrome). A case presentation and review of literature. *Niger J Med*. 2002;11(2):56–9.
 220. Scolapio JS, Savoy AD, Kaplan J, Burger CD, Lin SC. Sleep patterns of cyclic parenteral nutrition, a pilot study: are there sleepless nights? *J Parenter Enter Nutr*. 2002;26(3):214–7.
 221. Ortiz-Alvarez O, Cabral D, Prendiville JS, Stringer D, Petty RE, Malleson PN. Intestinal pseudo-obstruction as an initial presentation of systemic sclerosis in two children. *Br J Rheumatol*. 1997;36(2):280–4.
 222. Gohil A, Croffie JM, Fitzgerald JF, Gupta SK, Del Rosario MA. Reversible intestinal pseudoobstruction associated with neural crest tumors. *J Pediatr Gastroenterol Nutr*. 2001;33(1):86–8.
 223. Martin A, Messineo A, Lionetti P, Volta U, Stanghellini V, Barbara G, et al. A case of paraneoplastic inflammatory neuropathy of the gastrointestinal tract related to an underlying neuroblastoma: successful management with immunosuppressive therapy. *J Pediatr Gastroenterol Nutr*. 2008;46(4):457–60.
 224. Yakan S, Caliskan C, Kaplan H, Denecli AG, Coker A. Superior mesenteric artery syndrome: a rare cause of intestinal obstruction. Diagnosis and surgical management. *Indian J Surg*. 2013;75(2):106–10.
 225. Ariza A, Coll J, Fernandez-Figueras MT, Lopez MD, Mate JL, Garcia O, et al. Desmin myopathy: a multisystem disorder involving skeletal, cardiac, and smooth muscle. *Hum Pathol*. 1995;26(9):1032–7.

226. Krishnamurthy S, Heng Y, Schuffler MD. Chronic intestinal pseudo-obstruction in infants and children caused by diverse abnormalities of the myenteric plexus. *Gastroenterology*. 1993;104(5):1398–408.
227. Ko D, Yang H-B, Youn J, Kim H-Y. Clinical outcomes of pediatric chronic intestinal pseudo-obstruction. *J Clin Med*. 2021;10(11):2376.
228. Diamanti A, Fusaro F, Caldaro T, Capriati T, Candusso M, Nobili V, et al. Pediatric intestinal pseudo-obstruction: impact of neonatal and later onset on clinical and nutritional outcomes. *J Pediatr Gastroenterol Nutr*. 2019;69(2):212–7.
229. Camilleri M. Intestinal dysmotility: does the X-ray resolve the real dilemma? *J Pediatr Gastroenterol Nutr*. 1997;24(1):100–1.
230. Merlin A, Soyer P, Boudiaf M, Hamzi L, Rymer R. Chronic intestinal pseudo-obstruction in adult patients: multidetector row helical CT features. *Eur Radiol*. 2008;18(8):1587–95.
231. Ohkubo H, Kessoku T, Fuyuki A, Iida H, Inamori M, Fujii T, et al. Assessment of small bowel motility in patients with chronic intestinal pseudo-obstruction using cine-MRI. *Am J Gastroenterol*. 2013;108(7):1130–9.
232. Courtier J, Ohliger M, Rhee SJ, Terreblanche O, Heyman MB, MacKenzie JD. Shooting a moving target: use of real-time cine magnetic resonance imaging in assessment of the small bowel. *J Pediatr Gastroenterol Nutr*. 2013;57(4):426–31.
233. van Rijn KL, Bredenoord AJ, Smout AJPM, Bouma G, Tielbeek JAW, Horsthuis K, et al. Fasted and fed small bowel motility patterns at cine-MRI in chronic intestinal pseudo-obstruction. *Neurogastroenterol Motil*. 2021;33(6):e14062.
234. Fuyuki A, Ohkubo H, Higurashi T, Iida H, Inoh Y, Inamori M, et al. Clinical importance of cine-MRI assessment of small bowel motility in patients with chronic intestinal pseudo-obstruction: a retrospective study of 33 patients. *J Gastroenterol*. 2017;52(5):577–84.
235. Sato H, Ogiwara H, Takahashi K, Kawata Y, Kojima Y, Tominaga K, et al. New cine magnetic resonance imaging parameters for the differential diagnosis of chronic intestinal pseudo-obstruction. *Sci Rep*. 2021;11(1):22974.
236. Sumiyama K, Gostout CJ. Clinical applications of submucosal endoscopy. *Curr Opin Gastroenterol*. 2011;27(5):412–7.
237. Klibansky D, Rothstein R. Robotics in endoscopy. *Curr Opin Gastroenterol*. 2012;28(5):477–82.
238. Belkind-Gerson J, Tran K, Di Lorenzo C. Novel techniques to study colonic motor function in children. *Curr Gastroenterol Rep*. 2013;15(8):335.
239. Green AD, Belkind-Gerson J, Surjanhata BC, Mousa H, Kuo B, Di Lorenzo C. Wireless motility capsule test in children with upper gastrointestinal symptoms. *J Pediatr*. 2013;162(6):1181–7.
240. Sato H, Kamimura K, Matsui H, Owaki T, Morita S, Tanaka Y, et al. Esophageal high-resolution manometry for diagnosing the severity of the chronic intestinal pseudo-obstruction: a case series. *Dig Dis Sci*. 2021;66(11):3960–7.
241. Cucchiara S, Borrelli O, Salvia G, Iula VD, Fecarotta S, Gaudiello G, et al. A normal gastrointestinal motility excludes chronic intestinal pseudo-obstruction in children. *Dig Dis Sci*. 2000;45(2):258–64.
242. Hyman PE, McDiarmid SV, Napolitano J, Abrams CE, Tomomasa T. Antroduodenal motility in children with chronic intestinal pseudo-obstruction. *J Pediatr*. 1988;112(6):899–905.
243. Tomomasa T, Itoh Z, Koizumi T, Kitamura T, Suzuki N, Matsuyama S, et al. Manometric study on the intestinal motility in a case of megacystis-microcolon-intestinal hypoperistalsis syndrome. *J Pediatr Gastroenterol Nutr*. 1985;4(2):307–10.
244. Chanpong A, Cronin H, Rampling D, Ashworth M, Eaton S, Rybak A, et al. Enhancing the utility of antroduodenal manometry in pediatric intestinal pseudo-obstruction. *Neurogastroenterol Motil*. 2022;34(5):e14259.
245. Hyman PE, Di Lorenzo C, McAdams L, Flores AF, Tomomasa T, Garvey TQ III. Predicting the clinical response to cisapride in children with chronic intestinal pseudo-obstruction. *Am J Gastroenterol*. 1993;88(6):832–6.
246. Di Lorenzo C, Lucanto C, Flores AF, Idries S, Hyman PE. Effect of sequential erythromycin and octreotide on antroduodenal manometry. *J Pediatr Gastroenterol Nutr*. 1999;29(3):293–6.
247. Fell JM, Smith VV, Milla PJ. Infantile chronic idiopathic intestinal pseudo-obstruction: the role of small intestinal manometry as a diagnostic tool and prognostic indicator. *Gut*. 1996;39(2):306–11.
248. Summers RW, Anuras S, Green J. Jejunal manometry patterns in health, partial intestinal obstruction, and pseudo-obstruction. *Gastroenterology*. 1983;85(6):1290–300.
249. Camilleri M. Jejunal manometry in distal subacute mechanical obstruction: significance of prolonged simultaneous contractions. *Gut*. 1989;30(4):468–75.
250. Jinnouchi T, Sakurai Y, Miyoshi K, Koizumi C, Waki H, Kubota N, et al. A case of chronic intestinal pseudo-obstruction with mitochondrial diseases. *Intern Med*. 2022;61(4):469–74.
251. Hyman PE, Bursch B, Beck D, DiLorenzo C, Zeltzer LK. Discriminating pediatric condition falsification from chronic intestinal pseudo-obstruction in toddlers. *Child Maltreat*. 2002;7(2):132–7.
252. Hyman PE, Bursch B, Sood M, Schwankovsky L, Cocjin J, Zeltzer LK. Visceral pain-associated disability syndrome: a descriptive analysis. *J Pediatr Gastroenterol Nutr*. 2002;35(5):663–8.
253. Lyford G, Foxx-Orenstein A. Chronic intestinal pseudo-obstruction. *Curr Treat Options Gastroenterol*. 2004;7(4):317–25.
254. Di Lorenzo C, Flores AF, Buie T, Hyman PE. Intestinal motility and jejunal feeding in children with chronic intestinal pseudo-obstruction. *Gastroenterology*. 1995;108(5):1379–85.
255. Garipey CE, Mousa H. Clinical management of motility disorders in children. *Semin Pediatr Surg*. 2009;18(4):224–38.
256. Di Lorenzo C, Youssef NN. Diagnosis and management of intestinal motility disorders. *Semin Pediatr Surg*. 2010;19(1):50–8.
257. Longo WE, Vernava AM III. Prokinetic agents for lower gastrointestinal motility disorders. *Colon Rectum*. 1993;36(7):696–708.
258. Chini P, Toskes PP, Waseem S, Hou W, McDonald R, Moshiree B. Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. *Scand J Gastroenterol*. 2012;47(4):422–7.
259. Sorhaug S, Steinshamn SL, Waldum HL. Octreotide treatment for paraneoplastic intestinal pseudo-obstruction complicating SCLC. *Lung Cancer*. 2005;48(1):137–40.
260. Lee JW, Bang KW, Jang PS, Chung NG, Cho B, Jeong DC, et al. Neostigmine for the treatment of acute colonic pseudo-obstruction (ACPO) in pediatric hematologic malignancies. *Korean J Hematol*. 2010;45(1):62–5.
261. Lee H, Park S, Oh J-T, Kim HM, Kim S, Lee J-S. Oral pyridostigmine-responsive visceral myopathy with ACTG2 mutations: a case series. *J Pediatr Gastroenterol Nutr*. 2019;68(1):e16–7.
262. Manini ML, Camilleri M, Grothe R, Di Lorenzo C. Application of pyridostigmine in pediatric gastrointestinal motility disorders: a case series. *Paediatr Drugs*. 2018;20(2):173–80.
263. Mutalib M, Kammermeier J, Vora R, Borrelli O. Prucalopride in intestinal pseudo obstruction, paediatric experience and systematic review. *Acta Gastroenterol Belg*. 2021;84(3):429–34.
264. Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, et al. Systematic review: cardiovascular safety profile of 5-HT₄ agonists developed for gastrointestinal disorders. *Aliment Pharmacol Ther*. 2012;35(7):745–67.
265. Winter HS, Di Lorenzo C, Benninga MA, Gilger MA, Kearns GL, Hyman PE, et al. Oral prucalopride in children with functional constipation. *J Pediatr Gastroenterol Nutr*. 2013;57(2):197–203.

266. Chong K, Dhataria K. A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant. *Nat Rev Endocrinol.* 2009;5(5):285–8.
267. Tack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. *Aliment Pharmacol Ther.* 2005;22(9):847–53.
268. Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. *Dig Dis Sci.* 1995;40(9):1892–901.
269. Gu L, Ding C, Tian H, Yang B, Zhang X, Hua Y, et al. Serial frozen fecal microbiota transplantation in the treatment of chronic intestinal pseudo-obstruction: a preliminary study. *J Neurogastroenterol Motil.* 2017;23(2):289–97.
270. Pakarinen MP, Kurvinen A, Koivusalo AI, Ruuska T, Makisalo H, Jalanko H, et al. Surgical treatment and outcomes of severe pediatric intestinal motility disorders requiring parenteral nutrition. *J Pediatr Surg.* 2013;48(2):333–8.
271. Michaud L, Guimber D, Carpentier B, Sfeir R, Lambilliotte A, Mazingue F, et al. Gastrostomy as a decompression technique in children with chronic gastrointestinal obstruction. *J Pediatr Gastroenterol Nutr.* 2001;32(1):82–5.
272. Fonkalsrud EW, Pitt HA, Berquist WE, Ament ME. Surgical management of chronic intestinal pseudo-obstruction in infancy and childhood. *Prog Pediatr Surg.* 1989;24:221–5.
273. Pitt HA, Mann LL, Berquist WE, Ament ME, Fonkalsrud EW, DenBesten L. Chronic intestinal pseudo-obstruction. Management with total parenteral nutrition and a venting enterostomy. *Arch Surg.* 1985;120(5):614–8.
274. Connor FL, Di Lorenzo C. Chronic intestinal pseudo-obstruction: assessment and management. *Gastroenterology.* 2006;130(2 Suppl 1):S29–36.
275. Di Nardo G, Manca MB, Iannicelli E, D'Ambra G, Laviano A, Guarino M, et al. Percutaneous endoscopic gastrojejunostomy in pediatric intestinal pseudo-obstruction. *Nutrition.* 2021;86:111174.
276. Lapointe R. Chronic idiopathic intestinal pseudo-obstruction treated by near total small bowel resection: a 20-year experience. *J Gastrointest Surg.* 2010;14(12):1937–42.
277. Nunokawa T, Yokogawa N, Ohtsuka H, Shimada K, Sugii S. Transgastric long tube placement following percutaneous endoscopic gastrostomy for severe chronic intestinal pseudo-obstruction related to systemic sclerosis. *Mod Rheumatol.* 2015;25(6):958–61.
278. Goulet O, Sauvat F, Jan D. Surgery for pediatric patients with chronic intestinal pseudo-obstruction syndrome. *J Pediatr Gastroenterol Nutr.* 2005;41(Suppl 1):S66–8.
279. Pakarinen MP, Koivusalo AI, Rintala RJ. Outcomes of intestinal failure—a comparison between children with short bowel and dysmotile intestine. *J Pediatr Surg.* 2009;44(11):2139–44.
280. Irtan S, Bellaiche M, Brasher C, El Ghoneimi A, Cezard JP, Bonnard A. Stomal prolapse in children with chronic intestinal pseudoobstruction: a frequent complication? *J Pediatr Surg.* 2010;45(11):2234–7.
281. Vriesman MH, Noor N, Koppen IJ, Di Lorenzo C, de Jong JR, Benninga MA. Outcomes after enterostomies in children with and without motility disorders: a description and comparison of post-operative complications. *J Pediatr Surg.* 2020;55(11):2413–8.
282. Heitlinger LA, McClung HJ, Murray RD, Li BU. Recurrent pancreatitis in three patients with chronic idiopathic intestinal pseudo-obstruction. *J Pediatr Gastroenterol Nutr.* 1991;13(1):92–5.
283. Ordein JJ, Di Lorenzo C, Flores A, Hyman PE. Diversion colitis in children with severe gastrointestinal motility disorders. *Am J Gastroenterol.* 1992;87(1):88–90.
284. Rolston DD, Hunt JB, Fairclough PD, Wilks M, Levison DA, Clark ML, et al. Jejunal water and sodium secretion occurs in chronic idiopathic intestinal pseudo-obstruction. *J Clin Gastroenterol.* 1990;12(2):153–6.
285. Shiomura R, Tara S, Ito N, Watanabe M, Arai T, Kobayashi N, et al. Hemodynamic collapse caused by cardiac dysfunction and abdominal compartment syndrome in a patient with mitochondrial disease. *Intern Med.* 2022;61(4):489–93.
286. Goulet O, Jobert-Giraud A, Michel JL, Jaubert F, Lortat-Jacob S, Colomb V, et al. Chronic intestinal pseudo-obstruction syndrome in pediatric patients. *Eur J Pediatr Surg.* 1999;9(2):83–9.
287. Teich S, Mousa HM, Punati J, Di Lorenzo C. Efficacy of permanent gastric electrical stimulation for the treatment of gastroparesis and functional dyspepsia in children and adolescents. *J Pediatr Surg.* 2013;48(1):178–83.
288. Goldstein AM, Thapar N, Karunaratne TB, De Giorgio R. Clinical aspects of neurointestinal disease: pathophysiology, diagnosis, and treatment. *Dev Biol.* 2016;417(2):217–28.
289. Burns AJ, Goldstein AM, Newgreen DF, Stamp L, Schäfer K-H, Metzger M, et al. White paper on guidelines concerning enteric nervous system stem cell therapy for enteric neuropathies. *Dev Biol.* 2016;417(2):229–51.
290. Burns AJ, Thapar N. Neural stem cell therapies for enteric nervous system disorders. *Nat Rev Gastroenterol Hepatol.* 2014;11(5):317–28.
291. D'Antiga L, Goulet O. Intestinal failure in children: the European view. *J Pediatr Gastroenterol Nutr.* 2013;56(2):118–26.
292. Hukkinen M, Merras-Salmio L, Sipponen T, Mutanen A, Rintala RJ, Mäkisalo H, et al. Surgical rehabilitation of short and dysmotile intestine in children and adults. *Scand J Gastroenterol.* 2015;50(2):153–61.
293. Ganousse-Mazeron S, Lacaille F, Colomb-Jung V, Talbotec C, Ruemmele F, Sauvat F, et al. Assessment and outcome of children with intestinal failure referred for intestinal transplantation. *Clin Nutr.* 2015;34(3):428–35.
294. Millar AJ, Gupte G, Sharif K. Intestinal transplantation for motility disorders. *Semin Pediatr Surg.* 2009;18(4):258–62.
295. Sheth J, Sharif K, Lloyd C, Gupte G, Kelly D, de Ville de Goyet J, et al. Staged abdominal closure after small bowel or multivisceral transplantation. *Pediatr Transplant.* 2012;16(1):36–40.
296. Goulet O, Lacaille F, Colomb V, Jan D, Canioni D, Cezard J, et al. Intestinal transplantation in children: Paris experience. *Transpl Proc.* 2002;34(5):1887–8.
297. Loinaz C, Rodriguez MM, Kato T, Mittal N, Romaguera RL, Bruce JH, et al. Intestinal and multivisceral transplantation in children with severe gastrointestinal dysmotility. *J Pediatr Surg.* 2005;40(10):1598–604.
298. Minneci PC. Intestinal transplantation: an overview. *Pathophysiology.* 2014;21(1):119–22.
299. Sogawa H, Costa G, Armanyous S, Bond GJ, Cruz RJ, Humar A, et al. Twenty years of gut transplantation for chronic intestinal pseudo-obstruction: technical innovation, long-term outcome, quality of life, and disease recurrence. *Ann Surg.* 2021;273(2):325–33.
300. Iwarzon M, Gardulf A, Lindberg G. Functional status, health-related quality of life and symptom severity in patients with chronic intestinal pseudo-obstruction and enteric dysmotility. *Scand J Gastroenterol.* 2009;44(6):700–7.
301. Schwankovsky L, Mousa H, Rowhani A, Di Lorenzo C, Hyman PE. Quality of life outcomes in congenital chronic intestinal pseudo-obstruction. *Dig Dis Sci.* 2002;47(9):1965–8.
302. Çağan Appak Y, Baran M, Öztan MO, Karakoyun M, Turhan S, Tuğmen C, et al. Assessment and outcome of pediatric intestinal pseudo-obstruction: a tertiary-care-center experience from Turkey. *Turk J Gastroenterol.* 2019;30(4):357–63.
303. Smith VV, Milla PJ. Histological phenotypes of enteric smooth muscle disease causing functional intestinal obstruction in childhood. *Histopathology.* 1997;31(2):112–22.

304. Sonsino E, Mouy R, Foucaud P, Cezard JP, Aigrain Y, Bocquet L, et al. Intestinal pseudoobstruction related to cytomegalovirus infection of myenteric plexus. *N Engl J Med*. 1984;311(3):196-7.
305. Debinski HS, Kamm MA, Talbot IC, Khan G, Kangro HO, Jeffries DJ. DNA viruses in the pathogenesis of sporadic chronic idiopathic intestinal pseudo-obstruction. *Gut*. 1997;41(1):100-6.
306. Nowak TV, Goddard M, Batteiger B, Cummings OW. Evolution of acute cytomegalovirus gastritis to chronic gastrointestinal dysmotility in a nonimmunocompromised adult. *Gastroenterology*. 1999;116(4):953-8.
307. Anuras S, Mitros FA, Shirazi SS, Soper RT, Younoszai K, Green JB. Cardiac arrest in two children with nonfamilial chronic intestinal pseudoobstruction on total parenteral nutrition. *J Pediatr Gastroenterol Nutr*. 1982;1(1):137-44.